https://trial.medpath.com/news/personalized-mrna-cancer-vaccine-shows-promise-in-groundbreaking-bowel-cancer-trial 2025-06-16T19:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-mrna-cancer-vaccine-shows-promise-in-groundbreaking-bowel-cancer-trial 2025-06-16T19:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/supernus-pharmaceuticals-acquires-sage-therapeutics-for-795-million-strengthening-neuropsychiatry-portfolio 2025-06-16T18:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supernus-pharmaceuticals-acquires-sage-therapeutics-for-795-million-strengthening-neuropsychiatry-portfolio 2025-06-16T18:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/solu-therapeutics-appoints-enda-moran-as-coo-to-scale-cytac-platform-operations 2025-06-16T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solu-therapeutics-appoints-enda-moran-as-coo-to-scale-cytac-platform-operations 2025-06-16T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/supernus-pharmaceuticals-acquires-sage-therapeutics-for-up-to-795-million-securing-postpartum-depression-drug-zurzuvae 2025-06-16T17:12:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/supernus-pharmaceuticals-acquires-sage-therapeutics-for-up-to-795-million-securing-postpartum-depression-drug-zurzuvae 2025-06-16T17:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/liso-cel-achieves-95-5-response-rate-in-relapsed-refractory-marginal-zone-lymphoma 2025-06-16T17:11:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liso-cel-achieves-95-5-response-rate-in-relapsed-refractory-marginal-zone-lymphoma 2025-06-16T17:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/single-psilocybin-dose-provides-two-year-depression-relief-in-cancer-patients 2025-06-16T17:11:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-psilocybin-dose-provides-two-year-depression-relief-in-cancer-patients 2025-06-16T17:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/virogates-and-genspeed-achieve-breakthrough-in-point-of-care-chronic-inflammation-testing-for-longevity-market 2025-06-16T17:11:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virogates-and-genspeed-achieve-breakthrough-in-point-of-care-chronic-inflammation-testing-for-longevity-market 2025-06-16T17:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-submits-ind-application-for-once-monthly-obesity-drug-mbx-4291 2025-06-16T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mbx-biosciences-submits-ind-application-for-once-monthly-obesity-drug-mbx-4291 2025-06-16T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-loses-canadian-semaglutide-patent-protection-over-missed-450-fee-opening-door-to-generics-in-2026 2025-06-16T17:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-loses-canadian-semaglutide-patent-protection-over-missed-450-fee-opening-door-to-generics-in-2026 2025-06-16T17:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/bdd-pharma-s-oralogik-system-advances-timed-release-drug-delivery-for-adhd-and-rheumatoid-arthritis 2025-06-16T17:10:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bdd-pharma-s-oralogik-system-advances-timed-release-drug-delivery-for-adhd-and-rheumatoid-arthritis 2025-06-16T17:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-treated-with-novel-b-cell-targeting-therapy-for-myasthenia-gravis-in-phase-iii-trial 2025-06-16T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-treated-with-novel-b-cell-targeting-therapy-for-myasthenia-gravis-in-phase-iii-trial 2025-06-16T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/alzamend-neuro-completes-5-million-financing-to-advance-five-phase-ii-trials-for-al001-lithium-therapy 2025-06-16T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzamend-neuro-completes-5-million-financing-to-advance-five-phase-ii-trials-for-al001-lithium-therapy 2025-06-16T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/zircon-phase-3-trial-demonstrates-high-accuracy-of-novel-pet-tracer-for-kidney-cancer-detection 2025-06-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zircon-phase-3-trial-demonstrates-high-accuracy-of-novel-pet-tracer-for-kidney-cancer-detection 2025-06-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-sponsors-first-clinical-trial-of-needle-free-rotavirus-vaccine-using-dissolvable-microarray-patch-technology 2025-06-16T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-sponsors-first-clinical-trial-of-needle-free-rotavirus-vaccine-using-dissolvable-microarray-patch-technology 2025-06-16T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/teva-and-fosun-pharma-form-strategic-partnership-for-novel-anti-pd1-il2-cancer-immunotherapy-tev-56278 2025-06-16T16:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-and-fosun-pharma-form-strategic-partnership-for-novel-anti-pd1-il2-cancer-immunotherapy-tev-56278 2025-06-16T16:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/debiopharm-initiates-first-in-human-trial-of-cd37-targeted-adc-debio-1562m-for-relapsed-refractory-aml 2025-06-16T16:07:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/debiopharm-initiates-first-in-human-trial-of-cd37-targeted-adc-debio-1562m-for-relapsed-refractory-aml 2025-06-16T16:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-verona-trial-for-high-risk-myelodysplastic-syndrome-fails-to-meet-primary-survival-endpoint 2025-06-16T16:05:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-verona-trial-for-high-risk-myelodysplastic-syndrome-fails-to-meet-primary-survival-endpoint 2025-06-16T16:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/penumbra-completes-enrollment-in-landmark-storm-pe-trial-testing-thrombectomy-for-pulmonary-embolism 2025-06-16T16:05:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penumbra-completes-enrollment-in-landmark-storm-pe-trial-testing-thrombectomy-for-pulmonary-embolism 2025-06-16T16:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-molecules-completes-phase-1b-enrollment-for-novel-hsv-inhibitor-im-250 2025-06-16T16:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-molecules-completes-phase-1b-enrollment-for-novel-hsv-inhibitor-im-250 2025-06-16T16:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/xlife-sciences-expands-asian-footprint-through-strategic-partnerships-in-digital-health-and-precision-oncology 2025-06-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xlife-sciences-expands-asian-footprint-through-strategic-partnerships-in-digital-health-and-precision-oncology 2025-06-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurizon-s-nuz-001-demonstrates-neuroprotective-effects-in-huntington-s-disease-zebrafish-model 2025-06-16T15:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurizon-s-nuz-001-demonstrates-neuroprotective-effects-in-huntington-s-disease-zebrafish-model 2025-06-16T15:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/ubrigene-launches-gmp-compliant-ipsc-banks-to-accelerate-cell-therapy-development 2025-06-16T14:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ubrigene-launches-gmp-compliant-ipsc-banks-to-accelerate-cell-therapy-development 2025-06-16T14:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/quiver-bioscience-names-co-founder-graham-dempsey-ceo-to-advance-nav1-7-targeting-aso-for-chronic-pain 2025-06-16T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quiver-bioscience-names-co-founder-graham-dempsey-ceo-to-advance-nav1-7-targeting-aso-for-chronic-pain 2025-06-16T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/elite-pharmaceuticals-achieves-bioequivalence-for-generic-anticoagulant-in-27-billion-market 2025-06-16T12:54:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elite-pharmaceuticals-achieves-bioequivalence-for-generic-anticoagulant-in-27-billion-market 2025-06-16T12:54:45+00:00 hourly 0.9 https://trial.medpath.com/news/d-d-pharmatech-s-dd01-shows-rapid-liver-fat-reduction-in-mash-phase-2-trial-matching-competitor-results-in-quarter-of-the-time 2025-06-16T12:52:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/d-d-pharmatech-s-dd01-shows-rapid-liver-fat-reduction-in-mash-phase-2-trial-matching-competitor-results-in-quarter-of-the-time 2025-06-16T12:52:04+00:00 hourly 0.9 https://trial.medpath.com/news/circle-pharma-s-cid-078-receives-fda-orphan-drug-designation-for-small-cell-lung-cancer-treatment 2025-06-16T12:51:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circle-pharma-s-cid-078-receives-fda-orphan-drug-designation-for-small-cell-lung-cancer-treatment 2025-06-16T12:51:26+00:00 hourly 0.9 https://trial.medpath.com/news/nextcure-and-simcere-zaiming-form-strategic-partnership-for-cdh6-targeting-adc-sim0505 2025-06-16T12:51:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextcure-and-simcere-zaiming-form-strategic-partnership-for-cdh6-targeting-adc-sim0505 2025-06-16T12:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-s-inca033989-shows-86-response-rate-in-calr-mutant-blood-cancer-trial 2025-06-16T12:49:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-s-inca033989-shows-86-response-rate-in-calr-mutant-blood-cancer-trial 2025-06-16T12:49:47+00:00 hourly 0.9 https://trial.medpath.com/news/pierre-fabre-acquires-global-rights-to-next-generation-egfr-inhibitors-for-nsclc-treatment 2025-06-16T12:03:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pierre-fabre-acquires-global-rights-to-next-generation-egfr-inhibitors-for-nsclc-treatment 2025-06-16T12:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-blood-test-enables-celiac-disease-diagnosis-without-gluten-challenge 2025-06-16T12:02:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionary-blood-test-enables-celiac-disease-diagnosis-without-gluten-challenge 2025-06-16T12:02:30+00:00 hourly 0.9 https://trial.medpath.com/news/bluegenes-and-levrx-partner-to-integrate-real-time-pharmacogenetic-testing-into-pharmacy-benefit-systems 2025-06-16T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluegenes-and-levrx-partner-to-integrate-real-time-pharmacogenetic-testing-into-pharmacy-benefit-systems 2025-06-16T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-partners-with-university-of-alberta-to-advance-pnkp-inhibitor-research-for-glioblastoma-treatment 2025-06-16T08:49:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-partners-with-university-of-alberta-to-advance-pnkp-inhibitor-research-for-glioblastoma-treatment 2025-06-16T08:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/varenicline-bupropion-combination-shows-promise-for-alcohol-use-disorder-treatment 2025-06-16T08:48:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/varenicline-bupropion-combination-shows-promise-for-alcohol-use-disorder-treatment 2025-06-16T08:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/s-biomedics-reports-promising-12-month-data-for-parkinson-s-cell-therapy-a9-dpc-in-phase-1-2a-trial 2025-06-16T08:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/s-biomedics-reports-promising-12-month-data-for-parkinson-s-cell-therapy-a9-dpc-in-phase-1-2a-trial 2025-06-16T08:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/tg01-cancer-vaccine-shows-promising-clinical-activity-in-ras-mutant-multiple-myeloma 2025-06-16T08:47:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tg01-cancer-vaccine-shows-promising-clinical-activity-in-ras-mutant-multiple-myeloma 2025-06-16T08:47:36+00:00 hourly 0.9 https://trial.medpath.com/news/pulmovant-publishes-phase-1-data-supporting-once-daily-inhaled-mosliciguat-for-pulmonary-hypertension 2025-06-16T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulmovant-publishes-phase-1-data-supporting-once-daily-inhaled-mosliciguat-for-pulmonary-hypertension 2025-06-16T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/klotho-neurosciences-raises-11-million-through-warrant-exercises-achieves-debt-free-status 2025-06-16T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/klotho-neurosciences-raises-11-million-through-warrant-exercises-achieves-debt-free-status 2025-06-16T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/poltreg-establishes-u-s-subsidiary-immuthera-and-receives-positive-ema-opinion-for-type-1-diabetes-cell-therapy 2025-06-16T06:22:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poltreg-establishes-u-s-subsidiary-immuthera-and-receives-positive-ema-opinion-for-type-1-diabetes-cell-therapy 2025-06-16T06:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/olverembatinib-shows-promising-results-in-multiple-philadelphia-chromosome-positive-all-studies 2025-06-16T05:02:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olverembatinib-shows-promising-results-in-multiple-philadelphia-chromosome-positive-all-studies 2025-06-16T05:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/uk-flair-trial-demonstrates-superior-outcomes-with-chemotherapy-free-combination-therapy-for-chronic-lymphocytic-leukaemia 2025-06-16T00:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-flair-trial-demonstrates-superior-outcomes-with-chemotherapy-free-combination-therapy-for-chronic-lymphocytic-leukaemia 2025-06-16T00:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/adolore-biotherapeutics-reports-positive-preclinical-data-for-gene-therapy-targeting-chronic-knee-pain 2025-06-16T00:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adolore-biotherapeutics-reports-positive-preclinical-data-for-gene-therapy-targeting-chronic-knee-pain 2025-06-16T00:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-expands-into-preclinical-research-with-launch-of-samsung-organoids-drug-screening-platform 2025-06-16T00:46:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-expands-into-preclinical-research-with-launch-of-samsung-organoids-drug-screening-platform 2025-06-16T00:46:38+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-app-to-feature-clinical-trial-matching-system-as-uk-targets-150-day-setup-times 2025-06-16T00:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-app-to-feature-clinical-trial-matching-system-as-uk-targets-150-day-setup-times 2025-06-16T00:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/axcelead-and-a2-healthcare-form-strategic-partnership-to-accelerate-drug-r-d-in-japan 2025-06-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axcelead-and-a2-healthcare-form-strategic-partnership-to-accelerate-drug-r-d-in-japan 2025-06-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-and-kailera-present-phase-2-data-for-dual-glp-1-gip-agonist-and-oral-glp-1-therapies-at-ada-2025 2025-06-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-and-kailera-present-phase-2-data-for-dual-glp-1-gip-agonist-and-oral-glp-1-therapies-at-ada-2025 2025-06-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-formally-rescinds-laboratory-developed-test-rule-following-court-defeat 2025-06-15T21:03:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-formally-rescinds-laboratory-developed-test-rule-following-court-defeat 2025-06-15T21:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/novel-btk-degrader-bgb-16673-achieves-84-8-response-rate-in-heavily-pretreated-cll-sll-patients 2025-06-15T16:51:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-btk-degrader-bgb-16673-achieves-84-8-response-rate-in-heavily-pretreated-cll-sll-patients 2025-06-15T16:51:29+00:00 hourly 0.9 https://trial.medpath.com/news/intellia-s-crispr-gene-therapy-shows-98-reduction-in-hae-attacks-after-three-years 2025-06-15T16:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intellia-s-crispr-gene-therapy-shows-98-reduction-in-hae-attacks-after-three-years 2025-06-15T16:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/adalimumab-biosimilars-show-high-acceptance-and-long-term-durability-in-ibd-patients-across-age-groups 2025-06-15T08:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adalimumab-biosimilars-show-high-acceptance-and-long-term-durability-in-ibd-patients-across-age-groups 2025-06-15T08:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/socioeconomic-disparities-drive-worse-outcomes-in-multiple-myeloma-patients-despite-treatment-advances 2025-06-15T03:03:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/socioeconomic-disparities-drive-worse-outcomes-in-multiple-myeloma-patients-despite-treatment-advances 2025-06-15T03:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/eha-2025-showcases-breakthrough-therapies-for-hematologic-malignancies 2025-06-15T03:03:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eha-2025-showcases-breakthrough-therapies-for-hematologic-malignancies 2025-06-15T03:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/biologic-therapies-transform-respiratory-care-as-clinicians-embrace-earlier-precision-based-treatment-strategies 2025-06-15T03:02:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biologic-therapies-transform-respiratory-care-as-clinicians-embrace-earlier-precision-based-treatment-strategies 2025-06-15T03:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/sigachi-industries-secures-environmental-approval-for-major-api-manufacturing-facility-in-andhra-pradesh 2025-06-15T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sigachi-industries-secures-environmental-approval-for-major-api-manufacturing-facility-in-andhra-pradesh 2025-06-15T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/syngene-international-s-bengaluru-facility-receives-clean-fda-inspection-with-nai-status 2025-06-15T01:02:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syngene-international-s-bengaluru-facility-receives-clean-fda-inspection-with-nai-status 2025-06-15T01:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/twin-health-raises-53-million-to-scale-ai-powered-digital-twin-platform-for-metabolic-disease-management 2025-06-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/twin-health-raises-53-million-to-scale-ai-powered-digital-twin-platform-for-metabolic-disease-management 2025-06-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ethniq-launches-patented-natural-antifungal-treatment-showing-90-efficacy-in-clinical-trials 2025-06-14T23:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethniq-launches-patented-natural-antifungal-treatment-showing-90-efficacy-in-clinical-trials 2025-06-14T23:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-names-kirti-ganorkar-as-managing-director-in-major-leadership-transition 2025-06-14T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-names-kirti-ganorkar-as-managing-director-in-major-leadership-transition 2025-06-14T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/multimodal-ai-system-demonstrates-superior-survival-prediction-for-hepatocellular-carcinoma-immunotherapy 2025-06-14T21:04:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multimodal-ai-system-demonstrates-superior-survival-prediction-for-hepatocellular-carcinoma-immunotherapy 2025-06-14T21:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/nice-rejects-first-alzheimer-s-disease-modifying-drugs-for-nhs-use-due-to-cost-effectiveness-concerns 2025-06-14T20:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-rejects-first-alzheimer-s-disease-modifying-drugs-for-nhs-use-due-to-cost-effectiveness-concerns 2025-06-14T20:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/natco-pharma-s-mekaguda-api-facility-receives-fda-establishment-inspection-report-following-successful-remediation 2025-06-14T20:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natco-pharma-s-mekaguda-api-facility-receives-fda-establishment-inspection-report-following-successful-remediation 2025-06-14T20:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/inspiremd-receives-fda-approval-for-cguard-prime-carotid-stent-system-with-record-low-stroke-rates 2025-06-14T18:01:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inspiremd-receives-fda-approval-for-cguard-prime-carotid-stent-system-with-record-low-stroke-rates 2025-06-14T18:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapies-show-promise-for-severe-autoimmune-diseases-at-eular-2025 2025-06-14T17:00:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapies-show-promise-for-severe-autoimmune-diseases-at-eular-2025 2025-06-14T17:00:42+00:00 hourly 0.9 https://trial.medpath.com/news/benchling-partners-with-merck-to-streamline-vaccine-bioanalysis-through-integrated-digital-platform 2025-06-14T16:59:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benchling-partners-with-merck-to-streamline-vaccine-bioanalysis-through-integrated-digital-platform 2025-06-14T16:59:33+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-advances-targeted-protein-degradation-platform-with-new-clinical-data-at-eha-2025 2025-06-14T12:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-advances-targeted-protein-degradation-platform-with-new-clinical-data-at-eha-2025 2025-06-14T12:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-halol-facility-receives-eight-fda-observations-following-latest-inspection 2025-06-14T10:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-halol-facility-receives-eight-fda-observations-following-latest-inspection 2025-06-14T10:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/itm-to-present-phase-3-compete-trial-data-at-snmmi-2025-meeting 2025-06-14T05:02:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-to-present-phase-3-compete-trial-data-at-snmmi-2025-meeting 2025-06-14T05:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/regor-therapeutics-to-present-phase-2a-data-for-oral-glp-1-agonist-rgt-075-at-ada-2025 2025-06-14T04:02:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regor-therapeutics-to-present-phase-2a-data-for-oral-glp-1-agonist-rgt-075-at-ada-2025 2025-06-14T04:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/food-deserts-compound-clinical-trial-access-barriers-for-breast-cancer-patients 2025-06-14T03:02:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/food-deserts-compound-clinical-trial-access-barriers-for-breast-cancer-patients 2025-06-14T03:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-kalvista-s-sebetralstat-approval-decision-due-to-resource-constraints 2025-06-14T02:03:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-delays-kalvista-s-sebetralstat-approval-decision-due-to-resource-constraints 2025-06-14T02:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/intravenous-rehydration-shows-safety-in-severely-malnourished-children-challenging-who-guidelines 2025-06-14T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intravenous-rehydration-shows-safety-in-severely-malnourished-children-challenging-who-guidelines 2025-06-14T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-delays-sebetralstat-approval-decision-for-hereditary-angioedema-treatment-due-to-resource-constraints 2025-06-14T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-delays-sebetralstat-approval-decision-for-hereditary-angioedema-treatment-due-to-resource-constraints 2025-06-14T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/olutasidenib-maintenance-therapy-demonstrates-sustained-remission-in-idh1-mutated-aml-patients 2025-06-13T23:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olutasidenib-maintenance-therapy-demonstrates-sustained-remission-in-idh1-mutated-aml-patients 2025-06-13T23:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-explores-4-billion-diagnostics-unit-sale-to-streamline-portfolio 2025-06-13T22:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-explores-4-billion-diagnostics-unit-sale-to-streamline-portfolio 2025-06-13T22:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/neuroem-therapeutics-secures-1-33-million-in-series-a-funding-to-advance-drug-free-alzheimer-s-treatment 2025-06-13T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroem-therapeutics-secures-1-33-million-in-series-a-funding-to-advance-drug-free-alzheimer-s-treatment 2025-06-13T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/ponatinib-shows-superior-survival-outcomes-in-ph-all-patients-with-persistent-mrd-after-induction 2025-06-13T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ponatinib-shows-superior-survival-outcomes-in-ph-all-patients-with-persistent-mrd-after-induction 2025-06-13T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/nectero-medical-secures-cpt-codes-for-investigational-aaa-treatment-as-phase-2-3-trial-shows-promise 2025-06-13T21:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nectero-medical-secures-cpt-codes-for-investigational-aaa-treatment-as-phase-2-3-trial-shows-promise 2025-06-13T21:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/cyclophosphamide-plus-cyclosporin-emerges-as-new-standard-of-care-for-gvhd-prevention-in-blood-cancer-transplants 2025-06-13T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclophosphamide-plus-cyclosporin-emerges-as-new-standard-of-care-for-gvhd-prevention-in-blood-cancer-transplants 2025-06-13T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-advances-liposomal-cbd-platform-for-chronic-pain-as-peer-reviewed-study-highlights-non-opioid-alternative 2025-06-13T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocan-pharma-advances-liposomal-cbd-platform-for-chronic-pain-as-peer-reviewed-study-highlights-non-opioid-alternative 2025-06-13T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-first-eu-vaccine-against-swine-dysentery-targeting-disease-with-30-50-mortality-rate 2025-06-13T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-first-eu-vaccine-against-swine-dysentery-targeting-disease-with-30-50-mortality-rate 2025-06-13T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-launches-combine-pilot-program-to-streamline-combined-medicine-and-medical-device-studies 2025-06-13T20:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-launches-combine-pilot-program-to-streamline-combined-medicine-and-medical-device-studies 2025-06-13T20:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-class-cbp-p300-inhibitor-tt125-802-shows-promise-in-treatment-resistant-nsclc 2025-06-13T19:01:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-class-cbp-p300-inhibitor-tt125-802-shows-promise-in-treatment-resistant-nsclc 2025-06-13T19:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/ellipsis-health-raises-45m-series-a-to-launch-sage-ai-care-manager-with-emotional-intelligence 2025-06-13T19:01:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ellipsis-health-raises-45m-series-a-to-launch-sage-ai-care-manager-with-emotional-intelligence 2025-06-13T19:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/serum-institute-of-india-partners-with-dndi-to-develop-affordable-dengue-monoclonal-antibody-treatment 2025-06-13T17:12:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serum-institute-of-india-partners-with-dndi-to-develop-affordable-dengue-monoclonal-antibody-treatment 2025-06-13T17:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/fapi-based-pet-imaging-shows-superior-performance-over-fdg-pet-for-gastrointestinal-cancer-detection 2025-06-13T17:12:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fapi-based-pet-imaging-shows-superior-performance-over-fdg-pet-for-gastrointestinal-cancer-detection 2025-06-13T17:12:34+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-vaccination-reduces-severe-kidney-damage-risk-in-hospitalized-patients-ucla-study-finds 2025-06-13T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-vaccination-reduces-severe-kidney-damage-risk-in-hospitalized-patients-ucla-study-finds 2025-06-13T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-dual-targeting-car-t-therapy-achieves-80-complete-response-rate-in-lymphoma-trial 2025-06-13T17:11:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-dual-targeting-car-t-therapy-achieves-80-complete-response-rate-in-lymphoma-trial 2025-06-13T17:11:53+00:00 hourly 0.9 https://trial.medpath.com/news/nextcell-pharma-completes-patient-dosing-in-phase-ii-protrans-young-trial-for-pediatric-type-1-diabetes 2025-06-13T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextcell-pharma-completes-patient-dosing-in-phase-ii-protrans-young-trial-for-pediatric-type-1-diabetes 2025-06-13T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/vial-doses-first-participants-in-phase-1-trial-of-half-life-extended-anti-tl1a-antibody-for-ibd-treatment 2025-06-13T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vial-doses-first-participants-in-phase-1-trial-of-half-life-extended-anti-tl1a-antibody-for-ibd-treatment 2025-06-13T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/panavance-therapeutics-reports-promising-phase-1-results-for-misetionamide-in-pancreatic-cancer 2025-06-13T17:10:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panavance-therapeutics-reports-promising-phase-1-results-for-misetionamide-in-pancreatic-cancer 2025-06-13T17:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-announces-5-billion-u-s-biologics-manufacturing-investment-to-strengthen-supply-chain 2025-06-13T17:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-announces-5-billion-u-s-biologics-manufacturing-investment-to-strengthen-supply-chain 2025-06-13T17:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/pegloticase-achieves-complete-gout-remission-in-43-of-patients-after-52-weeks-of-treatment 2025-06-13T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pegloticase-achieves-complete-gout-remission-in-43-of-patients-after-52-weeks-of-treatment 2025-06-13T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-rocket-pharmaceuticals-gene-therapy-trial-after-patient-death 2025-06-13T16:01:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-clinical-hold-on-rocket-pharmaceuticals-gene-therapy-trial-after-patient-death 2025-06-13T16:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/citius-pharmaceuticals-closes-15-8m-direct-offering-to-fund-lymphir-commercial-launch 2025-06-13T15:03:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citius-pharmaceuticals-closes-15-8m-direct-offering-to-fund-lymphir-commercial-launch 2025-06-13T15:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/quest-diagnostics-partners-with-md-anderson-to-develop-multi-cancer-risk-blood-test-for-2026-launch 2025-06-13T14:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quest-diagnostics-partners-with-md-anderson-to-develop-multi-cancer-risk-blood-test-for-2026-launch 2025-06-13T14:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-pharmaceutical-launches-nabota-botulinum-toxin-in-qatar-completing-gulf-market-expansion 2025-06-13T14:03:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daewoong-pharmaceutical-launches-nabota-botulinum-toxin-in-qatar-completing-gulf-market-expansion 2025-06-13T14:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/medera-showcases-human-mini-heart-technology-breakthroughs-at-isscr-2025-advancing-gene-therapy-clinical-trials 2025-06-13T13:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medera-showcases-human-mini-heart-technology-breakthroughs-at-isscr-2025-advancing-gene-therapy-clinical-trials 2025-06-13T13:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/who-s-mrna-technology-transfer-programme-enters-phase-2-0-targeting-commercial-scale-production-in-low-and-middle-income-countries 2025-06-13T13:03:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-s-mrna-technology-transfer-programme-enters-phase-2-0-targeting-commercial-scale-production-in-low-and-middle-income-countries 2025-06-13T13:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/mrd-testing-emerges-as-key-decision-tool-for-post-transplant-multiple-myeloma-management 2025-06-13T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrd-testing-emerges-as-key-decision-tool-for-post-transplant-multiple-myeloma-management 2025-06-13T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/bcma-targeted-bispecific-antibody-cm336-shows-promise-for-refractory-autoimmune-hemolytic-anemia-in-nejm-study 2025-06-13T12:03:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bcma-targeted-bispecific-antibody-cm336-shows-promise-for-refractory-autoimmune-hemolytic-anemia-in-nejm-study 2025-06-13T12:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/dry-eye-disease-affects-16-4-million-americans-as-new-targeted-therapies-enter-development-pipeline 2025-06-13T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dry-eye-disease-affects-16-4-million-americans-as-new-targeted-therapies-enter-development-pipeline 2025-06-13T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/radiomedix-launches-raha-100-bench-top-generator-to-expand-lead-212-supply-for-targeted-alpha-therapy 2025-06-13T10:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiomedix-launches-raha-100-bench-top-generator-to-expand-lead-212-supply-for-targeted-alpha-therapy 2025-06-13T10:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapies-show-promise-for-idiopathic-pulmonary-fibrosis-and-progressive-pulmonary-fibrosis-treatment 2025-06-13T10:03:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-therapies-show-promise-for-idiopathic-pulmonary-fibrosis-and-progressive-pulmonary-fibrosis-treatment 2025-06-13T10:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-in-human-trial-for-novel-car-t-therapy-targeting-neuroblastoma 2025-06-13T08:49:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-in-human-trial-for-novel-car-t-therapy-targeting-neuroblastoma 2025-06-13T08:49:33+00:00 hourly 0.9 https://trial.medpath.com/news/large-real-world-study-finds-no-increased-cancer-or-cardiovascular-risk-with-jak-inhibitors-in-rheumatoid-arthritis 2025-06-13T08:49:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-real-world-study-finds-no-increased-cancer-or-cardiovascular-risk-with-jak-inhibitors-in-rheumatoid-arthritis 2025-06-13T08:49:31+00:00 hourly 0.9 https://trial.medpath.com/news/mitsubishi-research-institute-and-astellas-partner-to-accelerate-japanese-drug-discovery-startups 2025-06-13T08:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitsubishi-research-institute-and-astellas-partner-to-accelerate-japanese-drug-discovery-startups 2025-06-13T08:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/merry-life-advances-first-in-class-alzheimer-s-drug-tml-6-to-global-phase-ii-trial 2025-06-13T08:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merry-life-advances-first-in-class-alzheimer-s-drug-tml-6-to-global-phase-ii-trial 2025-06-13T08:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-secures-up-to-22-million-to-advance-phase-3-ataxia-telangiectasia-trial 2025-06-13T08:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quince-therapeutics-secures-up-to-22-million-to-advance-phase-3-ataxia-telangiectasia-trial 2025-06-13T08:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/viz-ai-receives-first-fda-clearance-for-ai-powered-subdural-hemorrhage-measurement-technology 2025-06-13T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viz-ai-receives-first-fda-clearance-for-ai-powered-subdural-hemorrhage-measurement-technology 2025-06-13T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/prolaris-genomic-test-advances-personalized-prostate-cancer-treatment-with-precision-therapy-selection 2025-06-13T05:03:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prolaris-genomic-test-advances-personalized-prostate-cancer-treatment-with-precision-therapy-selection 2025-06-13T05:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-to-present-phase-3-results-of-dual-glp-1-glucagon-receptor-agonist-mazdutide-at-ada-2025 2025-06-13T03:10:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-to-present-phase-3-results-of-dual-glp-1-glucagon-receptor-agonist-mazdutide-at-ada-2025 2025-06-13T03:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/early-colorectal-cancer-screening-at-age-40-reduces-death-risk-by-39-taiwan-study-shows 2025-06-13T03:09:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-colorectal-cancer-screening-at-age-40-reduces-death-risk-by-39-taiwan-study-shows 2025-06-13T03:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-secures-french-regulatory-pathway-for-lumevoq-gene-therapy-in-rare-blindness-disease 2025-06-13T02:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensight-biologics-secures-french-regulatory-pathway-for-lumevoq-gene-therapy-in-rare-blindness-disease 2025-06-13T02:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-becomes-first-health-system-globally-to-approve-trojan-horse-cancer-therapy-for-multiple-myeloma 2025-06-13T01:05:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-becomes-first-health-system-globally-to-approve-trojan-horse-cancer-therapy-for-multiple-myeloma 2025-06-13T01:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/iom-bioworks-secures-rs-4-crore-seed-funding-to-advance-ai-powered-gut-microbiome-healthcare-platform 2025-06-13T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iom-bioworks-secures-rs-4-crore-seed-funding-to-advance-ai-powered-gut-microbiome-healthcare-platform 2025-06-13T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/starton-therapeutics-launches-phase-2a-trial-for-continuous-low-dose-lenalidomide-in-multiple-myeloma 2025-06-13T01:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/starton-therapeutics-launches-phase-2a-trial-for-continuous-low-dose-lenalidomide-in-multiple-myeloma 2025-06-13T01:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-launch-world-first-clinical-trial-of-pmr-116-to-target-undruggable-myc-driven-cancers 2025-06-13T01:03:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-researchers-launch-world-first-clinical-trial-of-pmr-116-to-target-undruggable-myc-driven-cancers 2025-06-13T01:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/elanco-s-zenrelia-receives-positive-eu-regulatory-opinion-for-canine-allergic-dermatitis-treatment 2025-06-13T01:02:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elanco-s-zenrelia-receives-positive-eu-regulatory-opinion-for-canine-allergic-dermatitis-treatment 2025-06-13T01:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/merck-animal-health-receives-eu-regulatory-milestone-for-first-in-class-jak-inhibitor-numelvi-for-canine-allergic-dermatitis 2025-06-13T01:02:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-animal-health-receives-eu-regulatory-milestone-for-first-in-class-jak-inhibitor-numelvi-for-canine-allergic-dermatitis 2025-06-13T01:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-pain-market-poised-for-transformation-with-novel-non-opioid-therapies-by-2034 2025-06-13T01:01:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-pain-market-poised-for-transformation-with-novel-non-opioid-therapies-by-2034 2025-06-13T01:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/tazemetostat-pinometostat-combination-shows-promise-for-b-cell-lymphoma-treatment-resistance 2025-06-13T00:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tazemetostat-pinometostat-combination-shows-promise-for-b-cell-lymphoma-treatment-resistance 2025-06-13T00:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/silence-therapeutics-reports-promising-phase-1-data-for-divesiran-in-polycythemia-vera-at-eha-2025 2025-06-13T00:04:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silence-therapeutics-reports-promising-phase-1-data-for-divesiran-in-polycythemia-vera-at-eha-2025 2025-06-13T00:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-roche-abbvie-s-venclexta-plus-gazyva-as-first-line-chemotherapy-free-treatment-for-cll 2025-06-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-roche-abbvie-s-venclexta-plus-gazyva-as-first-line-chemotherapy-free-treatment-for-cll 2025-06-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tekton-research-adds-fourth-clinical-site-in-2025-with-richmond-pediatric-associates-partnership 2025-06-12T23:05:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tekton-research-adds-fourth-clinical-site-in-2025-with-richmond-pediatric-associates-partnership 2025-06-12T23:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/ouro-medicines-initiates-phase-1b-trial-of-om336-in-autoimmune-cytopenias-following-fda-orphan-drug-designation 2025-06-12T23:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ouro-medicines-initiates-phase-1b-trial-of-om336-in-autoimmune-cytopenias-following-fda-orphan-drug-designation 2025-06-12T23:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/courage-therapeutics-appoints-giovanni-ferrara-as-ceo-to-advance-melanocortin-targeted-obesity-treatments 2025-06-12T21:12:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/courage-therapeutics-appoints-giovanni-ferrara-as-ceo-to-advance-melanocortin-targeted-obesity-treatments 2025-06-12T21:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-non-surgical-treatment-for-non-muscle-invasive-bladder-cancer 2025-06-12T21:11:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-non-surgical-treatment-for-non-muscle-invasive-bladder-cancer 2025-06-12T21:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/major-us-pharmaceutical-wholesalers-expand-market-control-through-strategic-practice-management-acquisitions 2025-06-12T21:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-us-pharmaceutical-wholesalers-expand-market-control-through-strategic-practice-management-acquisitions 2025-06-12T21:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/bbot-s-bbo-10203-shows-broad-anti-tumor-activity-in-science-publication-advances-to-phase-1-trial 2025-06-12T21:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bbot-s-bbo-10203-shows-broad-anti-tumor-activity-in-science-publication-advances-to-phase-1-trial 2025-06-12T21:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/autonomize-ai-secures-28-million-series-a-to-scale-ai-driven-healthcare-operations-platform 2025-06-12T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autonomize-ai-secures-28-million-series-a-to-scale-ai-driven-healthcare-operations-platform 2025-06-12T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-grants-orphan-drug-designation-to-florbetaben-18f-for-attr-amyloidosis-diagnosis 2025-06-12T21:05:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-grants-orphan-drug-designation-to-florbetaben-18f-for-attr-amyloidosis-diagnosis 2025-06-12T21:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/parallel-bio-raises-21-million-series-a-to-revolutionize-drug-discovery-with-human-organoid-platform 2025-06-12T21:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parallel-bio-raises-21-million-series-a-to-revolutionize-drug-discovery-with-human-organoid-platform 2025-06-12T21:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/specialised-therapeutics-expands-incyte-partnership-to-bring-two-novel-cancer-therapies-to-asia-pacific 2025-06-12T20:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/specialised-therapeutics-expands-incyte-partnership-to-bring-two-novel-cancer-therapies-to-asia-pacific 2025-06-12T20:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/apex-labs-expands-phase-2b-psilocybin-ptsd-trial-to-israel-with-ministry-of-health-approval 2025-06-12T20:04:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apex-labs-expands-phase-2b-psilocybin-ptsd-trial-to-israel-with-ministry-of-health-approval 2025-06-12T20:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-bleximenib-shows-promising-results-in-phase-1b-aml-trial-with-82-response-rate 2025-06-12T18:01:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-bleximenib-shows-promising-results-in-phase-1b-aml-trial-with-82-response-rate 2025-06-12T18:01:36+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-invalidation-of-agilent-s-crispr-guide-rna-patents-in-synthego-victory 2025-06-12T18:00:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-upholds-invalidation-of-agilent-s-crispr-guide-rna-patents-in-synthego-victory 2025-06-12T18:00:38+00:00 hourly 0.9 https://trial.medpath.com/news/scinai-immunotherapeutics-secures-1-38m-funding-as-cdmo-business-accelerates-toward-2m-revenue-target 2025-06-12T17:18:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scinai-immunotherapeutics-secures-1-38m-funding-as-cdmo-business-accelerates-toward-2m-revenue-target 2025-06-12T17:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-inc-negotiates-strategic-partnership-changes-with-german-parent-company 2025-06-12T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-inc-negotiates-strategic-partnership-changes-with-german-parent-company 2025-06-12T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/alys-pharmaceuticals-advances-first-in-class-mast-cell-selective-c-kit-inhibitor-aly-301-to-clinical-trials-for-cold-urticaria 2025-06-12T17:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alys-pharmaceuticals-advances-first-in-class-mast-cell-selective-c-kit-inhibitor-aly-301-to-clinical-trials-for-cold-urticaria 2025-06-12T17:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-secures-japanese-patent-for-novel-mast-cell-targeting-platform-ht-kit 2025-06-12T17:15:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-secures-japanese-patent-for-novel-mast-cell-targeting-platform-ht-kit 2025-06-12T17:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/volition-s-nu-q-h3-1-biomarker-shows-promise-for-sepsis-assessment-in-large-icu-study 2025-06-12T17:14:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/volition-s-nu-q-h3-1-biomarker-shows-promise-for-sepsis-assessment-in-large-icu-study 2025-06-12T17:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/cmv-treatment-pipeline-expands-with-20-therapies-from-leading-pharmaceutical-companies 2025-06-12T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cmv-treatment-pipeline-expands-with-20-therapies-from-leading-pharmaceutical-companies 2025-06-12T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/chlorhexidine-impregnated-central-venous-catheters-reduce-icu-bloodstream-infections-by-70-5-in-multinational-study 2025-06-12T17:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chlorhexidine-impregnated-central-venous-catheters-reduce-icu-bloodstream-infections-by-70-5-in-multinational-study 2025-06-12T17:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/vascarta-s-vasceptor-receives-fda-orphan-drug-designation-for-sickle-cell-disease-treatment 2025-06-12T17:14:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vascarta-s-vasceptor-receives-fda-orphan-drug-designation-for-sickle-cell-disease-treatment 2025-06-12T17:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/adc-therapeutics-secures-100-million-financing-to-advance-zynlonta-development-through-2028 2025-06-12T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adc-therapeutics-secures-100-million-financing-to-advance-zynlonta-development-through-2028 2025-06-12T17:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/dyne-therapeutics-reports-breakthrough-preclinical-results-for-fshd-gene-therapy-dyne-302 2025-06-12T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dyne-therapeutics-reports-breakthrough-preclinical-results-for-fshd-gene-therapy-dyne-302 2025-06-12T17:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/rebel-medicine-secures-6m-series-a-funding-and-fda-ind-clearance-for-non-opioid-pain-therapy-alevatrix 2025-06-12T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rebel-medicine-secures-6m-series-a-funding-and-fda-ind-clearance-for-non-opioid-pain-therapy-alevatrix 2025-06-12T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/bullfrog-ai-partners-with-sygnature-discovery-to-expand-ai-driven-drug-discovery-platform-access 2025-06-12T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bullfrog-ai-partners-with-sygnature-discovery-to-expand-ai-driven-drug-discovery-platform-access 2025-06-12T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/predictive-oncology-develops-exclusive-3d-liver-toxicity-models-for-labcorp-to-accelerate-drug-discovery 2025-06-12T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/predictive-oncology-develops-exclusive-3d-liver-toxicity-models-for-labcorp-to-accelerate-drug-discovery 2025-06-12T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/alzecure-receives-fda-support-for-acd440-development-in-rare-pain-disorder-erythromelalgia 2025-06-12T17:11:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzecure-receives-fda-support-for-acd440-development-in-rare-pain-disorder-erythromelalgia 2025-06-12T17:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-sumitomo-s-nuvisertib-for-myelofibrosis-treatment 2025-06-12T17:11:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-sumitomo-s-nuvisertib-for-myelofibrosis-treatment 2025-06-12T17:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/syensqo-opens-world-s-largest-microbiology-lab-in-france-to-accelerate-biodegradable-product-development 2025-06-12T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syensqo-opens-world-s-largest-microbiology-lab-in-france-to-accelerate-biodegradable-product-development 2025-06-12T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-secures-manufacturing-patent-for-ampligen-through-2041 2025-06-12T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aim-immunotech-secures-manufacturing-patent-for-ampligen-through-2041 2025-06-12T17:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/screenin3d-secures-ps750000-to-accelerate-cancer-drug-development-with-lab-on-a-chip-technology 2025-06-12T17:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/screenin3d-secures-ps750000-to-accelerate-cancer-drug-development-with-lab-on-a-chip-technology 2025-06-12T17:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-secures-fda-approval-for-generic-prednisolone-acetate-eye-drops-targeting-201-million-market 2025-06-12T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-secures-fda-approval-for-generic-prednisolone-acetate-eye-drops-targeting-201-million-market 2025-06-12T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/nanoform-initiates-pivotal-bioequivalence-studies-for-nanoenzalutamide-prostate-cancer-treatment 2025-06-12T17:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoform-initiates-pivotal-bioequivalence-studies-for-nanoenzalutamide-prostate-cancer-treatment 2025-06-12T17:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/immunoprecise-s-ai-designed-glp-1-peptides-outperform-semaglutide-in-receptor-activation-studies 2025-06-12T14:03:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunoprecise-s-ai-designed-glp-1-peptides-outperform-semaglutide-in-receptor-activation-studies 2025-06-12T14:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/mina-therapeutics-reports-breakthrough-pre-clinical-results-for-rna-based-sickle-cell-disease-treatment 2025-06-12T14:02:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mina-therapeutics-reports-breakthrough-pre-clinical-results-for-rna-based-sickle-cell-disease-treatment 2025-06-12T14:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-analysis-reveals-943-autoimmune-collaboration-and-licensing-deals-across-30-diseases-from-2016-2025 2025-06-12T12:51:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-analysis-reveals-943-autoimmune-collaboration-and-licensing-deals-across-30-diseases-from-2016-2025 2025-06-12T12:51:42+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-to-acquire-curevac-for-1-25-billion-to-strengthen-mrna-cancer-immunotherapy-pipeline 2025-06-12T12:50:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-to-acquire-curevac-for-1-25-billion-to-strengthen-mrna-cancer-immunotherapy-pipeline 2025-06-12T12:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/sensible-biotechnologies-achieves-90-reduction-in-mrna-optimization-time-using-ai-powered-platform 2025-06-12T12:50:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensible-biotechnologies-achieves-90-reduction-in-mrna-optimization-time-using-ai-powered-platform 2025-06-12T12:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/cytiva-completes-1-6-billion-global-manufacturing-expansion-to-boost-biopharmaceutical-supply-chain 2025-06-12T12:49:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytiva-completes-1-6-billion-global-manufacturing-expansion-to-boost-biopharmaceutical-supply-chain 2025-06-12T12:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/kaist-researchers-develop-antibody-treatment-to-restore-vision-in-retinitis-pigmentosa 2025-06-12T12:47:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaist-researchers-develop-antibody-treatment-to-restore-vision-in-retinitis-pigmentosa 2025-06-12T12:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/merck-launches-phase-3-trial-for-single-dose-dengue-vaccine-v181-targeting-global-public-health-crisis 2025-06-12T12:46:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-launches-phase-3-trial-for-single-dose-dengue-vaccine-v181-targeting-global-public-health-crisis 2025-06-12T12:46:36+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antimicrobial-strategies-show-promise-against-drug-resistant-pathogens 2025-06-12T10:01:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-antimicrobial-strategies-show-promise-against-drug-resistant-pathogens 2025-06-12T10:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/mezzion-secures-20-million-to-advance-phase-3-trial-of-udenafil-for-rare-congenital-heart-disease 2025-06-12T09:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mezzion-secures-20-million-to-advance-phase-3-trial-of-udenafil-for-rare-congenital-heart-disease 2025-06-12T09:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/spikimm-secures-worldwide-license-for-anti-bk-virus-monoclonal-antibodies-to-protect-transplant-patients 2025-06-12T09:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spikimm-secures-worldwide-license-for-anti-bk-virus-monoclonal-antibodies-to-protect-transplant-patients 2025-06-12T09:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/astrivax-therapeutics-appoints-former-bayer-pharma-ceo-dieter-weinand-as-board-chairman 2025-06-12T09:06:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrivax-therapeutics-appoints-former-bayer-pharma-ceo-dieter-weinand-as-board-chairman 2025-06-12T09:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-secures-19-million-to-advance-novel-oncomimics-immunotherapy-for-indolent-non-hodgkin-lymphoma 2025-06-12T09:05:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterome-secures-19-million-to-advance-novel-oncomimics-immunotherapy-for-indolent-non-hodgkin-lymphoma 2025-06-12T09:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-reports-breakthrough-results-from-in-vivo-gene-therapy-ctx310-for-heart-disease 2025-06-12T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-reports-breakthrough-results-from-in-vivo-gene-therapy-ctx310-for-heart-disease 2025-06-12T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-reports-sustained-safety-profile-for-epysqli-biosimilar-in-long-term-pnh-study 2025-06-12T09:03:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-reports-sustained-safety-profile-for-epysqli-biosimilar-in-long-term-pnh-study 2025-06-12T09:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/snipr-biome-doses-first-patient-with-crispr-armed-phage-therapy-snipr001-for-drug-resistant-e-coli-prevention 2025-06-12T09:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/snipr-biome-doses-first-patient-with-crispr-armed-phage-therapy-snipr001-for-drug-resistant-e-coli-prevention 2025-06-12T09:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/cytovale-s-intellisep-diagnostic-reduces-sepsis-mortality-by-39-in-large-real-world-study 2025-06-12T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytovale-s-intellisep-diagnostic-reduces-sepsis-mortality-by-39-in-large-real-world-study 2025-06-12T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/mro-acquires-q-centrix-to-create-comprehensive-clinical-data-management-platform 2025-06-12T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mro-acquires-q-centrix-to-create-comprehensive-clinical-data-management-platform 2025-06-12T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/moleculight-fluorescence-imaging-demonstrates-superior-outcomes-in-deep-sternal-wound-infections-reducing-costs-and-complications 2025-06-12T06:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moleculight-fluorescence-imaging-demonstrates-superior-outcomes-in-deep-sternal-wound-infections-reducing-costs-and-complications 2025-06-12T06:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/cognito-therapeutics-spectris-ad-demonstrates-significant-delay-in-alzheimer-s-disease-progression-through-non-invasive-neuromodulation 2025-06-12T06:02:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognito-therapeutics-spectris-ad-demonstrates-significant-delay-in-alzheimer-s-disease-progression-through-non-invasive-neuromodulation 2025-06-12T06:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/qlaris-bio-develops-novel-fixed-dose-combination-therapy-targeting-unaddressed-component-of-glaucoma-treatment 2025-06-12T06:01:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qlaris-bio-develops-novel-fixed-dose-combination-therapy-targeting-unaddressed-component-of-glaucoma-treatment 2025-06-12T06:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/juvena-therapeutics-partners-with-eli-lilly-in-ai-driven-muscle-health-drug-discovery-collaboration 2025-06-12T05:03:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/juvena-therapeutics-partners-with-eli-lilly-in-ai-driven-muscle-health-drug-discovery-collaboration 2025-06-12T05:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/rutgers-study-challenges-fda-heart-safety-warning-for-epilepsy-drug-lamotrigine 2025-06-12T05:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rutgers-study-challenges-fda-heart-safety-warning-for-epilepsy-drug-lamotrigine 2025-06-12T05:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-replaces-entire-cdc-vaccine-advisory-committee-with-eight-new-members 2025-06-12T03:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rfk-jr-replaces-entire-cdc-vaccine-advisory-committee-with-eight-new-members 2025-06-12T03:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-oncology-drug-delivery-transforms-cancer-care-with-fda-approved-formulations 2025-06-12T03:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-oncology-drug-delivery-transforms-cancer-care-with-fda-approved-formulations 2025-06-12T03:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/toripalimab-emerges-as-preferred-pd-1-inhibitor-for-metastatic-nasopharyngeal-carcinoma-despite-access-challenges 2025-06-12T03:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/toripalimab-emerges-as-preferred-pd-1-inhibitor-for-metastatic-nasopharyngeal-carcinoma-despite-access-challenges 2025-06-12T03:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/monopar-therapeutics-launches-fda-authorized-expanded-access-program-for-upar-targeted-radiopharmaceuticals-in-advanced-cancers 2025-06-12T01:05:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monopar-therapeutics-launches-fda-authorized-expanded-access-program-for-upar-targeted-radiopharmaceuticals-in-advanced-cancers 2025-06-12T01:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-partners-reports-promising-response-rates-with-optimized-mp0533-dosing-in-relapsed-refractory-aml 2025-06-12T01:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-partners-reports-promising-response-rates-with-optimized-mp0533-dosing-in-relapsed-refractory-aml 2025-06-12T01:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/skin-biopsy-test-detects-neurodegenerative-biomarker-in-75-of-rem-sleep-disorder-patients 2025-06-12T01:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skin-biopsy-test-detects-neurodegenerative-biomarker-in-75-of-rem-sleep-disorder-patients 2025-06-12T01:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/olaparib-temozolomide-combination-fails-to-improve-outcomes-in-advanced-uterine-leiomyosarcoma 2025-06-12T01:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olaparib-temozolomide-combination-fails-to-improve-outcomes-in-advanced-uterine-leiomyosarcoma 2025-06-12T01:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-seeks-external-partners-to-fund-late-stage-vaccine-trials-for-latent-virus-programs 2025-06-12T01:03:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-seeks-external-partners-to-fund-late-stage-vaccine-trials-for-latent-virus-programs 2025-06-12T01:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/university-at-buffalo-develops-novel-non-opioid-molecule-for-long-lasting-chronic-pain-relief 2025-06-12T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-at-buffalo-develops-novel-non-opioid-molecule-for-long-lasting-chronic-pain-relief 2025-06-12T00:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/ryght-ai-secures-3m-seed-funding-and-expands-academic-partnerships-to-accelerate-clinical-trial-site-selection 2025-06-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryght-ai-secures-3m-seed-funding-and-expands-academic-partnerships-to-accelerate-clinical-trial-site-selection 2025-06-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-completes-11-2-billion-spin-off-from-novartis-becomes-independent-generics-leader 2025-06-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-completes-11-2-billion-spin-off-from-novartis-becomes-independent-generics-leader 2025-06-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-tamarack-biotics-uv-light-milk-treatment-technology-as-safe-alternative-to-traditional-pasteurization 2025-06-11T21:31:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-tamarack-biotics-uv-light-milk-treatment-technology-as-safe-alternative-to-traditional-pasteurization 2025-06-11T21:31:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-tablet-formulation-of-brukinsa-for-all-indications-reducing-pill-burden-for-b-cell-cancer-patients 2025-06-11T21:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-new-tablet-formulation-of-brukinsa-for-all-indications-reducing-pill-burden-for-b-cell-cancer-patients 2025-06-11T21:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/aspirin-shows-no-benefit-and-potential-harm-in-colorectal-cancer-liver-metastases-phase-3-trial-finds 2025-06-11T21:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspirin-shows-no-benefit-and-potential-harm-in-colorectal-cancer-liver-metastases-phase-3-trial-finds 2025-06-11T21:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/t1d-exchange-to-present-13-real-world-data-studies-at-ada-2025-scientific-sessions 2025-06-11T21:02:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/t1d-exchange-to-present-13-real-world-data-studies-at-ada-2025-scientific-sessions 2025-06-11T21:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/okyo-pharma-s-eye-pain-drug-trial-ends-early-analysts-raise-price-target-60-on-accelerated-timeline 2025-06-11T21:00:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/okyo-pharma-s-eye-pain-drug-trial-ends-early-analysts-raise-price-target-60-on-accelerated-timeline 2025-06-11T21:00:55+00:00 hourly 0.9 https://trial.medpath.com/news/northwest-biotherapeutics-to-present-next-generation-dendritic-cell-therapy-advances-at-cancer-immunotherapy-conference 2025-06-11T20:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwest-biotherapeutics-to-present-next-generation-dendritic-cell-therapy-advances-at-cancer-immunotherapy-conference 2025-06-11T20:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/nusano-achieves-99-2-purity-in-gadolinium-160-enrichment-opens-190000-square-foot-utah-facility 2025-06-11T20:09:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nusano-achieves-99-2-purity-in-gadolinium-160-enrichment-opens-190000-square-foot-utah-facility 2025-06-11T20:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-acquires-novel-prostate-cancer-radiopharmaceutical-for-1-35-billion 2025-06-11T20:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-acquires-novel-prostate-cancer-radiopharmaceutical-for-1-35-billion 2025-06-11T20:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/uniqure-appoints-kylie-o-keefe-as-chief-customer-and-strategy-officer-to-lead-amt-130-commercialization-for-huntington-s-disease 2025-06-11T20:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uniqure-appoints-kylie-o-keefe-as-chief-customer-and-strategy-officer-to-lead-amt-130-commercialization-for-huntington-s-disease 2025-06-11T20:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/biovica-sets-ambitious-revenue-targets-following-strategic-partnerships-in-cancer-monitoring 2025-06-11T20:03:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovica-sets-ambitious-revenue-targets-following-strategic-partnerships-in-cancer-monitoring 2025-06-11T20:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/sofinnova-partners-and-nvidia-launch-ai-infrastructure-partnership-to-accelerate-european-life-sciences-innovation 2025-06-11T18:00:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sofinnova-partners-and-nvidia-launch-ai-infrastructure-partnership-to-accelerate-european-life-sciences-innovation 2025-06-11T18:00:17+00:00 hourly 0.9 https://trial.medpath.com/news/lifordi-presents-promising-preclinical-data-for-lfd-200-glucocorticoid-adc-at-eular-2025 2025-06-11T17:13:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifordi-presents-promising-preclinical-data-for-lfd-200-glucocorticoid-adc-at-eular-2025 2025-06-11T17:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/setpoint-medical-s-neuroimmune-modulation-platform-receives-eular-clinical-research-award-for-rheumatoid-arthritis-trial 2025-06-11T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/setpoint-medical-s-neuroimmune-modulation-platform-receives-eular-clinical-research-award-for-rheumatoid-arthritis-trial 2025-06-11T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-mavyret-as-first-treatment-for-acute-hepatitis-c-with-96-cure-rate-in-eight-weeks 2025-06-11T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-mavyret-as-first-treatment-for-acute-hepatitis-c-with-96-cure-rate-in-eight-weeks 2025-06-11T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/zeteo-biomedical-secures-global-patents-for-advanced-drug-delivery-technologies-supporting-space-based-healthcare 2025-06-11T17:11:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeteo-biomedical-secures-global-patents-for-advanced-drug-delivery-technologies-supporting-space-based-healthcare 2025-06-11T17:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/nanobody-platform-enhances-cancer-immunotherapy-through-albumin-hitchhiking-and-sting-activation 2025-06-11T17:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanobody-platform-enhances-cancer-immunotherapy-through-albumin-hitchhiking-and-sting-activation 2025-06-11T17:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/chiesi-group-and-key2brain-expand-partnership-with-worldwide-licensing-deal-for-blood-brain-barrier-crossing-therapies 2025-06-11T17:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chiesi-group-and-key2brain-expand-partnership-with-worldwide-licensing-deal-for-blood-brain-barrier-crossing-therapies 2025-06-11T17:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/cabaletta-bio-launches-public-offering-to-fund-car-t-cell-therapy-development-for-autoimmune-diseases 2025-06-11T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cabaletta-bio-launches-public-offering-to-fund-car-t-cell-therapy-development-for-autoimmune-diseases 2025-06-11T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/graves-disease-pipeline-shows-promise-with-10-therapies-in-development-as-ted-treatments-gain-regulatory-momentum 2025-06-11T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/graves-disease-pipeline-shows-promise-with-10-therapies-in-development-as-ted-treatments-gain-regulatory-momentum 2025-06-11T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/essilorluxottica-acquires-european-ophthalmology-network-optegra-to-advance-med-tech-strategy 2025-06-11T17:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essilorluxottica-acquires-european-ophthalmology-network-optegra-to-advance-med-tech-strategy 2025-06-11T17:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/simtra-biopharma-solutions-and-milliporesigma-form-strategic-alliance-to-streamline-adc-manufacturing 2025-06-11T17:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simtra-biopharma-solutions-and-milliporesigma-form-strategic-alliance-to-streamline-adc-manufacturing 2025-06-11T17:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/elkedonia-raises-eur11-25-million-to-develop-novel-neuroplastogen-therapy-for-treatment-resistant-depression 2025-06-11T17:03:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elkedonia-raises-eur11-25-million-to-develop-novel-neuroplastogen-therapy-for-treatment-resistant-depression 2025-06-11T17:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-bp1-15205-shows-breakthrough-potential-as-best-in-class-narcolepsy-treatment 2025-06-11T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmony-biosciences-bp1-15205-shows-breakthrough-potential-as-best-in-class-narcolepsy-treatment 2025-06-11T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/walnut-hill-medical-selected-as-fda-tap-program-advisor-to-accelerate-medical-device-patient-access 2025-06-11T17:02:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/walnut-hill-medical-selected-as-fda-tap-program-advisor-to-accelerate-medical-device-patient-access 2025-06-11T17:02:08+00:00 hourly 0.9 https://trial.medpath.com/news/seastar-medical-s-scd-therapy-receives-2-million-dod-grant-for-military-burn-and-sepsis-research 2025-06-11T17:02:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seastar-medical-s-scd-therapy-receives-2-million-dod-grant-for-military-burn-and-sepsis-research 2025-06-11T17:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/medable-launches-ai-powered-partner-program-to-accelerate-clinical-trial-startup-by-50 2025-06-11T16:03:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medable-launches-ai-powered-partner-program-to-accelerate-clinical-trial-startup-by-50 2025-06-11T16:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-s-iopofosine-i-131-doubles-survival-in-pediatric-brain-cancer-trial 2025-06-11T16:03:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-s-iopofosine-i-131-doubles-survival-in-pediatric-brain-cancer-trial 2025-06-11T16:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/energenesis-biomedical-advances-first-in-class-parkinson-s-disease-therapy-energi-f705pd-toward-phase-i-data-readout 2025-06-11T16:01:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/energenesis-biomedical-advances-first-in-class-parkinson-s-disease-therapy-energi-f705pd-toward-phase-i-data-readout 2025-06-11T16:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/induction-chemoimmunotherapy-shows-non-inferior-outcomes-to-consolidation-therapy-in-stage-iii-nsclc 2025-06-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/induction-chemoimmunotherapy-shows-non-inferior-outcomes-to-consolidation-therapy-in-stage-iii-nsclc 2025-06-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-combines-personalized-neoantigen-vaccines-with-radiotherapy-for-advanced-cancer-treatment 2025-06-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-combines-personalized-neoantigen-vaccines-with-radiotherapy-for-advanced-cancer-treatment 2025-06-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ascend-advanced-therapies-achieves-gmp-certification-for-aav-gene-therapy-quality-control-in-munich 2025-06-11T15:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascend-advanced-therapies-achieves-gmp-certification-for-aav-gene-therapy-quality-control-in-munich 2025-06-11T15:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/cogent-biosciences-secures-400m-debt-financing-to-advance-bezuclastinib-through-pivotal-trials 2025-06-11T15:01:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cogent-biosciences-secures-400m-debt-financing-to-advance-bezuclastinib-through-pivotal-trials 2025-06-11T15:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/triplet-therapy-shows-superior-efficacy-in-braf-mutant-melanoma-brain-metastases 2025-06-11T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triplet-therapy-shows-superior-efficacy-in-braf-mutant-melanoma-brain-metastases 2025-06-11T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/capstan-therapeutics-initiates-first-in-human-trial-of-novel-in-vivo-car-t-therapy-for-autoimmune-diseases 2025-06-11T14:01:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capstan-therapeutics-initiates-first-in-human-trial-of-novel-in-vivo-car-t-therapy-for-autoimmune-diseases 2025-06-11T14:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytics-biotech-appoints-2b-deal-architect-as-ceo-to-advance-pelareorep-immunotherapy 2025-06-11T13:00:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncolytics-biotech-appoints-2b-deal-architect-as-ceo-to-advance-pelareorep-immunotherapy 2025-06-11T13:00:05+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-launches-new-phase-3-trial-for-cagrisema-following-mixed-redefine-1-results 2025-06-11T12:59:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-launches-new-phase-3-trial-for-cagrisema-following-mixed-redefine-1-results 2025-06-11T12:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-s-nadunolimab-receives-fda-fast-track-designation-for-metastatic-pancreatic-cancer 2025-06-11T12:57:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cantargia-s-nadunolimab-receives-fda-fast-track-designation-for-metastatic-pancreatic-cancer 2025-06-11T12:57:17+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-and-nvidia-launch-ai-orchestrator-agents-to-accelerate-clinical-research-and-drug-development 2025-06-11T12:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-and-nvidia-launch-ai-orchestrator-agents-to-accelerate-clinical-research-and-drug-development 2025-06-11T12:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/memo-therapeutics-demonstrates-therapeutic-antibodies-can-cross-kidney-barrier-supporting-bk-virus-treatment-approach 2025-06-11T11:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memo-therapeutics-demonstrates-therapeutic-antibodies-can-cross-kidney-barrier-supporting-bk-virus-treatment-approach 2025-06-11T11:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/israeli-researchers-develop-bioengineered-skin-graft-that-accelerates-burn-healing-by-50 2025-06-11T10:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/israeli-researchers-develop-bioengineered-skin-graft-that-accelerates-burn-healing-by-50 2025-06-11T10:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-and-broad-institute-extend-cardiovascular-research-partnership-through-2030 2025-06-11T10:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-and-broad-institute-extend-cardiovascular-research-partnership-through-2030 2025-06-11T10:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-subsidiary-rayzebio-acquires-oncoacp3-radiopharmaceutical-for-prostate-cancer-in-1-35-billion-deal 2025-06-11T10:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-subsidiary-rayzebio-acquires-oncoacp3-radiopharmaceutical-for-prostate-cancer-in-1-35-billion-deal 2025-06-11T10:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/splicebio-raises-135-million-series-b-to-advance-first-dual-aav-gene-therapy-for-stargardt-disease 2025-06-11T10:01:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splicebio-raises-135-million-series-b-to-advance-first-dual-aav-gene-therapy-for-stargardt-disease 2025-06-11T10:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-in-class-influenza-drug-onradivir-targeting-novel-pb2-protein 2025-06-11T09:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-in-class-influenza-drug-onradivir-targeting-novel-pb2-protein 2025-06-11T09:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/splicebio-raises-135-million-series-b-to-advance-gene-therapy-for-stargardt-disease-using-novel-protein-splicing-platform 2025-06-11T09:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/splicebio-raises-135-million-series-b-to-advance-gene-therapy-for-stargardt-disease-using-novel-protein-splicing-platform 2025-06-11T09:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/maxcyte-and-ori-biotech-partner-to-enhance-car-t-cell-manufacturing-through-platform-integration 2025-06-11T09:02:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxcyte-and-ori-biotech-partner-to-enhance-car-t-cell-manufacturing-through-platform-integration 2025-06-11T09:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-s-bi-1206-shows-promising-phase-1-results-in-combination-with-pembrolizumab-for-solid-tumors 2025-06-11T09:02:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-s-bi-1206-shows-promising-phase-1-results-in-combination-with-pembrolizumab-for-solid-tumors 2025-06-11T09:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/solvonis-therapeutics-launches-ai-powered-cns-drug-discovery-platform-for-depression-and-addiction 2025-06-11T09:01:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solvonis-therapeutics-launches-ai-powered-cns-drug-discovery-platform-for-depression-and-addiction 2025-06-11T09:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-pharmaceutical-partners-with-salipro-biotech-to-target-challenging-membrane-proteins-for-drug-discovery 2025-06-11T09:01:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daewoong-pharmaceutical-partners-with-salipro-biotech-to-target-challenging-membrane-proteins-for-drug-discovery 2025-06-11T09:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/genepowerx-partners-with-mgi-tech-to-advance-ai-powered-genomic-solutions-for-personalized-medicine 2025-06-11T09:01:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genepowerx-partners-with-mgi-tech-to-advance-ai-powered-genomic-solutions-for-personalized-medicine 2025-06-11T09:01:02+00:00 hourly 0.9 https://trial.medpath.com/news/cadila-pharmaceuticals-launches-biscado-bisoprolol-to-address-india-s-cardiovascular-disease-burden 2025-06-11T08:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadila-pharmaceuticals-launches-biscado-bisoprolol-to-address-india-s-cardiovascular-disease-burden 2025-06-11T08:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/hemab-therapeutics-advances-bleeding-disorder-pipeline-with-promising-clinical-data-at-isth-2025 2025-06-11T08:02:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemab-therapeutics-advances-bleeding-disorder-pipeline-with-promising-clinical-data-at-isth-2025 2025-06-11T08:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/xl-protein-grants-worldwide-license-to-grifols-for-pasylation-enhanced-biopharmaceutical-development 2025-06-11T07:02:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xl-protein-grants-worldwide-license-to-grifols-for-pasylation-enhanced-biopharmaceutical-development 2025-06-11T07:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/xprotm-shows-promise-in-reducing-alzheimer-s-pathology-following-traumatic-brain-injury-in-preclinical-study 2025-06-11T06:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xprotm-shows-promise-in-reducing-alzheimer-s-pathology-following-traumatic-brain-injury-in-preclinical-study 2025-06-11T06:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/femasys-partners-with-carolinas-fertility-institute-to-expand-femaseed-access-across-north-carolina-network 2025-06-11T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/femasys-partners-with-carolinas-fertility-institute-to-expand-femaseed-access-across-north-carolina-network 2025-06-11T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/weekly-oral-risperidone-shows-promise-for-schizophrenia-treatment-in-phase-3-trial 2025-06-11T05:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weekly-oral-risperidone-shows-promise-for-schizophrenia-treatment-in-phase-3-trial 2025-06-11T05:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/onesource-specialty-pharma-partners-with-xbrane-biopharma-for-commercial-biosimilar-manufacturing 2025-06-11T05:02:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onesource-specialty-pharma-partners-with-xbrane-biopharma-for-commercial-biosimilar-manufacturing 2025-06-11T05:02:03+00:00 hourly 0.9 https://trial.medpath.com/news/cyclopharm-secures-maximum-5-year-us-patent-extension-for-technegas-lung-imaging-agent-through-2031 2025-06-11T05:02:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclopharm-secures-maximum-5-year-us-patent-extension-for-technegas-lung-imaging-agent-through-2031 2025-06-11T05:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/modified-dash-diet-shows-significant-blood-pressure-benefits-in-type-2-diabetes-patients 2025-06-11T05:00:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modified-dash-diet-shows-significant-blood-pressure-benefits-in-type-2-diabetes-patients 2025-06-11T05:00:30+00:00 hourly 0.9 https://trial.medpath.com/news/angle-s-parsortix-system-enables-breakthrough-cancer-research-revealing-ctc-clusters-as-key-metastatic-drivers 2025-06-11T03:02:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/angle-s-parsortix-system-enables-breakthrough-cancer-research-revealing-ctc-clusters-as-key-metastatic-drivers 2025-06-11T03:02:53+00:00 hourly 0.9 https://trial.medpath.com/news/hypha-labs-advances-ai-powered-mushroom-cultivation-technology-with-new-patent-filings 2025-06-11T02:05:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypha-labs-advances-ai-powered-mushroom-cultivation-technology-with-new-patent-filings 2025-06-11T02:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/antibiotic-ciprofloxacin-shows-novel-ace-inhibition-mechanism-opening-path-to-improved-hypertension-therapies 2025-06-11T00:50:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antibiotic-ciprofloxacin-shows-novel-ace-inhibition-mechanism-opening-path-to-improved-hypertension-therapies 2025-06-11T00:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/eli-health-raises-12m-series-a-to-commercialize-instant-saliva-based-hormone-monitoring-system 2025-06-11T00:49:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-health-raises-12m-series-a-to-commercialize-instant-saliva-based-hormone-monitoring-system 2025-06-11T00:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/network-meta-analysis-reveals-comparable-cardiovascular-benefits-between-pcsk9-inhibitors-alirocumab-and-evolocumab 2025-06-11T00:47:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/network-meta-analysis-reveals-comparable-cardiovascular-benefits-between-pcsk9-inhibitors-alirocumab-and-evolocumab 2025-06-11T00:47:13+00:00 hourly 0.9 https://trial.medpath.com/news/sifi-merges-with-faes-farma-to-expand-global-access-to-akantior-first-approved-therapy-for-rare-eye-infection 2025-06-11T00:47:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sifi-merges-with-faes-farma-to-expand-global-access-to-akantior-first-approved-therapy-for-rare-eye-infection 2025-06-11T00:47:07+00:00 hourly 0.9 https://trial.medpath.com/news/us-universities-drive-87-of-academic-patents-supporting-fda-drug-approvals-from-2020-2024 2025-06-11T00:47:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-universities-drive-87-of-academic-patents-supporting-fda-drug-approvals-from-2020-2024 2025-06-11T00:47:06+00:00 hourly 0.9 https://trial.medpath.com/news/semaglutide-demonstrates-safety-and-efficacy-for-weight-loss-in-schizophrenia-patients 2025-06-11T00:46:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semaglutide-demonstrates-safety-and-efficacy-for-weight-loss-in-schizophrenia-patients 2025-06-11T00:46:54+00:00 hourly 0.9 https://trial.medpath.com/news/nicoya-lifesciences-acquires-applied-photophysics-to-create-integrated-biologics-characterization-platform 2025-06-11T00:46:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nicoya-lifesciences-acquires-applied-photophysics-to-create-integrated-biologics-characterization-platform 2025-06-11T00:46:51+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-mosunetuzumab-shows-promise-in-untreated-b-cell-lymphomas-with-durable-responses 2025-06-11T00:46:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-mosunetuzumab-shows-promise-in-untreated-b-cell-lymphomas-with-durable-responses 2025-06-11T00:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/bexorg-partners-with-biohaven-to-advance-cns-drug-development-using-ai-driven-whole-brain-discovery-platform 2025-06-11T00:46:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bexorg-partners-with-biohaven-to-advance-cns-drug-development-using-ai-driven-whole-brain-discovery-platform 2025-06-11T00:46:31+00:00 hourly 0.9 https://trial.medpath.com/news/b-cell-depletion-therapy-shows-promise-for-nmosd-treatment-through-comprehensive-immune-system-modulation 2025-06-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-cell-depletion-therapy-shows-promise-for-nmosd-treatment-through-comprehensive-immune-system-modulation 2025-06-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/green-valley-pharmaceutical-suspends-production-of-controversial-alzheimer-s-drug-gv-971-amid-license-renewal 2025-06-10T21:00:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/green-valley-pharmaceutical-suspends-production-of-controversial-alzheimer-s-drug-gv-971-amid-license-renewal 2025-06-10T21:00:28+00:00 hourly 0.9 https://trial.medpath.com/news/us-small-molecule-api-cdmo-market-projected-to-reach-12-49-billion-by-2030-driven-by-fda-approvals-and-hpapi-demand 2025-06-10T19:54:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-small-molecule-api-cdmo-market-projected-to-reach-12-49-billion-by-2030-driven-by-fda-approvals-and-hpapi-demand 2025-06-10T19:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/nuevocor-receives-fda-ind-clearance-for-gene-therapy-targeting-rare-genetic-heart-disease 2025-06-10T18:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuevocor-receives-fda-ind-clearance-for-gene-therapy-targeting-rare-genetic-heart-disease 2025-06-10T18:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-manufacturing-issues-delay-unicycive-s-kidney-disease-drug-approval-process 2025-06-10T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-manufacturing-issues-delay-unicycive-s-kidney-disease-drug-approval-process 2025-06-10T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-skyrizi-and-rinvoq-drive-recovery-as-humira-sales-plummet-50-following-patent-loss 2025-06-10T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-skyrizi-and-rinvoq-drive-recovery-as-humira-sales-plummet-50-following-patent-loss 2025-06-10T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/aiml-innovations-secures-provisional-patents-for-ai-powered-ecg-signal-processing-technology 2025-06-10T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aiml-innovations-secures-provisional-patents-for-ai-powered-ecg-signal-processing-technology 2025-06-10T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-exercises-option-for-quell-s-car-treg-therapy-in-inflammatory-bowel-disease 2025-06-10T17:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-exercises-option-for-quell-s-car-treg-therapy-in-inflammatory-bowel-disease 2025-06-10T17:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/gyre-therapeutics-initiates-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china 2025-06-10T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gyre-therapeutics-initiates-phase-1-trial-of-f230-for-pulmonary-arterial-hypertension-in-china 2025-06-10T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-biopharmaceuticals-appoints-michael-vasconcelles-as-head-of-r-d-to-drive-pipeline-expansion 2025-06-10T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/day-one-biopharmaceuticals-appoints-michael-vasconcelles-as-head-of-r-d-to-drive-pipeline-expansion 2025-06-10T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/curadev-and-memorial-sloan-kettering-expand-collaboration-to-advance-novel-sting-agonist-crd3874-si 2025-06-10T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curadev-and-memorial-sloan-kettering-expand-collaboration-to-advance-novel-sting-agonist-crd3874-si 2025-06-10T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/32-biosciences-secures-6-million-funding-to-advance-gut-microbiome-diagnostic-and-therapeutic-platform 2025-06-10T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/32-biosciences-secures-6-million-funding-to-advance-gut-microbiome-diagnostic-and-therapeutic-platform 2025-06-10T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/vanda-pharmaceuticals-initiates-first-in-human-trial-of-personalized-aso-therapy-vca-894a-for-ultra-rare-cmt2s 2025-06-10T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanda-pharmaceuticals-initiates-first-in-human-trial-of-personalized-aso-therapy-vca-894a-for-ultra-rare-cmt2s 2025-06-10T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-s-tpip-achieves-breakthrough-results-in-phase-2b-pah-trial-with-35-reduction-in-pulmonary-vascular-resistance 2025-06-10T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-s-tpip-achieves-breakthrough-results-in-phase-2b-pah-trial-with-35-reduction-in-pulmonary-vascular-resistance 2025-06-10T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/caliway-unveils-cbl-514-preclinical-data-for-glp-1-weight-rebound-prevention-at-bio-2025 2025-06-10T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caliway-unveils-cbl-514-preclinical-data-for-glp-1-weight-rebound-prevention-at-bio-2025 2025-06-10T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-therapeutics-receives-fda-clearance-for-mrt-8102-first-nek7-targeted-molecular-glue-degrader-for-inflammatory-diseases 2025-06-10T17:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monte-rosa-therapeutics-receives-fda-clearance-for-mrt-8102-first-nek7-targeted-molecular-glue-degrader-for-inflammatory-diseases 2025-06-10T17:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/evogene-completes-first-in-class-ai-foundation-model-for-small-molecule-design-with-90-precision 2025-06-10T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evogene-completes-first-in-class-ai-foundation-model-for-small-molecule-design-with-90-precision 2025-06-10T17:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/silicogenix-partners-with-bioduro-to-accelerate-ai-driven-drug-discovery-for-complex-diseases 2025-06-10T17:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silicogenix-partners-with-bioduro-to-accelerate-ai-driven-drug-discovery-for-complex-diseases 2025-06-10T17:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/immvira-initiates-phase-ii-trial-for-novel-oncolytic-immunotherapy-in-bcg-unresponsive-bladder-cancer 2025-06-10T16:16:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immvira-initiates-phase-ii-trial-for-novel-oncolytic-immunotherapy-in-bcg-unresponsive-bladder-cancer 2025-06-10T16:16:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-xifyrm-injectable-meloxicam-for-moderate-to-severe-pain-management 2025-06-10T16:14:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-xifyrm-injectable-meloxicam-for-moderate-to-severe-pain-management 2025-06-10T16:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-gilead-s-weekly-hiv-combination-therapy-following-safety-signal 2025-06-10T16:12:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-clinical-hold-on-gilead-s-weekly-hiv-combination-therapy-following-safety-signal 2025-06-10T16:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/hellocare-ai-partners-with-mayo-clinic-to-develop-ambient-clinical-intelligence-technology 2025-06-10T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hellocare-ai-partners-with-mayo-clinic-to-develop-ambient-clinical-intelligence-technology 2025-06-10T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/antares-therapeutics-launches-with-177-million-series-a-to-advance-first-in-class-cancer-precision-medicines 2025-06-10T14:01:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antares-therapeutics-launches-with-177-million-series-a-to-advance-first-in-class-cancer-precision-medicines 2025-06-10T14:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/centauri-therapeutics-demonstrates-novel-immunotherapy-approach-against-multi-drug-resistant-gram-negative-infections 2025-06-10T13:03:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centauri-therapeutics-demonstrates-novel-immunotherapy-approach-against-multi-drug-resistant-gram-negative-infections 2025-06-10T13:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-becomes-first-european-health-system-to-trial-revolutionary-histotripsy-cancer-treatment 2025-06-10T13:02:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-becomes-first-european-health-system-to-trial-revolutionary-histotripsy-cancer-treatment 2025-06-10T13:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/tagomics-secures-ps860k-grant-to-develop-novel-multiomics-test-for-early-colorectal-cancer-detection 2025-06-10T13:02:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tagomics-secures-ps860k-grant-to-develop-novel-multiomics-test-for-early-colorectal-cancer-detection 2025-06-10T13:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/cellex-expands-gmp-manufacturing-capacity-following-production-of-over-5800-cell-and-gene-therapy-batches 2025-06-10T13:02:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellex-expands-gmp-manufacturing-capacity-following-production-of-over-5800-cell-and-gene-therapy-batches 2025-06-10T13:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/cn-bio-expands-fda-recognized-dili-assay-with-cross-species-models-to-improve-drug-safety-predictions 2025-06-10T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cn-bio-expands-fda-recognized-dili-assay-with-cross-species-models-to-improve-drug-safety-predictions 2025-06-10T13:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/emulate-launches-high-throughput-ava-system-to-replace-animal-testing-in-drug-development 2025-06-10T13:02:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emulate-launches-high-throughput-ava-system-to-replace-animal-testing-in-drug-development 2025-06-10T13:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-partners-with-virogen-to-advance-first-in-class-anti-cd3-immunotoxin-vg712-toward-commercial-manufacturing 2025-06-10T13:02:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-partners-with-virogen-to-advance-first-in-class-anti-cd3-immunotoxin-vg712-toward-commercial-manufacturing 2025-06-10T13:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/inflation-reduction-act-to-lower-btk-inhibitor-costs-potentially-transforming-cll-and-mcl-treatment-access 2025-06-10T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflation-reduction-act-to-lower-btk-inhibitor-costs-potentially-transforming-cll-and-mcl-treatment-access 2025-06-10T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/novoviah-s-novoleukintm-platform-achieves-90-sensitivity-in-celiac-disease-detection-through-novel-t-cell-testing 2025-06-10T10:36:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novoviah-s-novoleukintm-platform-achieves-90-sensitivity-in-celiac-disease-detection-through-novel-t-cell-testing 2025-06-10T10:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/uspto-denies-irhythm-patent-challenges-for-vital-signs-monitoring-technology 2025-06-10T08:46:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uspto-denies-irhythm-patent-challenges-for-vital-signs-monitoring-technology 2025-06-10T08:46:52+00:00 hourly 0.9 https://trial.medpath.com/news/ezz-life-science-secures-21m-distribution-agreement-for-genomic-wellness-products-in-southeast-asia 2025-06-10T08:45:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ezz-life-science-secures-21m-distribution-agreement-for-genomic-wellness-products-in-southeast-asia 2025-06-10T08:45:38+00:00 hourly 0.9 https://trial.medpath.com/news/smartphone-app-delivers-breakthrough-in-huntington-s-disease-clinical-trial-efficiency 2025-06-10T07:59:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smartphone-app-delivers-breakthrough-in-huntington-s-disease-clinical-trial-efficiency 2025-06-10T07:59:28+00:00 hourly 0.9 https://trial.medpath.com/news/renaissthera-advances-ai-designed-oral-obesity-drug-targeting-gipr-to-lead-optimization 2025-06-10T06:01:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renaissthera-advances-ai-designed-oral-obesity-drug-targeting-gipr-to-lead-optimization 2025-06-10T06:01:28+00:00 hourly 0.9 https://trial.medpath.com/news/alexion-partners-with-pangaea-data-to-develop-ai-system-for-hypophosphatasia-detection 2025-06-10T05:02:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alexion-partners-with-pangaea-data-to-develop-ai-system-for-hypophosphatasia-detection 2025-06-10T05:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/taconic-biosciences-secures-exclusive-crispr-license-from-helmholtz-munich-to-enhance-animal-model-generation 2025-06-10T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taconic-biosciences-secures-exclusive-crispr-license-from-helmholtz-munich-to-enhance-animal-model-generation 2025-06-10T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-syntara-s-snt-5505-for-myelofibrosis-treatment 2025-06-10T05:00:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-syntara-s-snt-5505-for-myelofibrosis-treatment 2025-06-10T05:00:03+00:00 hourly 0.9 https://trial.medpath.com/news/macrogenics-secures-70-million-in-zynyz-royalty-deal-extends-cash-runway-through-2027 2025-06-10T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macrogenics-secures-70-million-in-zynyz-royalty-deal-extends-cash-runway-through-2027 2025-06-10T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-of-niraparib-dostarlimab-combination-fails-to-meet-primary-endpoint-in-recurrent-head-and-neck-cancer 2025-06-10T03:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-of-niraparib-dostarlimab-combination-fails-to-meet-primary-endpoint-in-recurrent-head-and-neck-cancer 2025-06-10T03:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/national-resilience-winds-down-six-manufacturing-facilities-despite-2-25-billion-in-total-funding 2025-06-10T01:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-resilience-winds-down-six-manufacturing-facilities-despite-2-25-billion-in-total-funding 2025-06-10T01:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/aribio-and-arcera-forge-600-million-partnership-for-novel-alzheimer-s-drug-ar1001 2025-06-10T01:04:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aribio-and-arcera-forge-600-million-partnership-for-novel-alzheimer-s-drug-ar1001 2025-06-10T01:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/sentio-biosciences-announces-10-6-million-expansion-to-boost-domestic-generic-drug-manufacturing 2025-06-10T01:04:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sentio-biosciences-announces-10-6-million-expansion-to-boost-domestic-generic-drug-manufacturing 2025-06-10T01:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/cgas-sting-pathway-shows-dual-role-in-breast-cancer-immunotherapy-response 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cgas-sting-pathway-shows-dual-role-in-breast-cancer-immunotherapy-response 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nordic-capital-invests-in-minerva-imaging-to-build-global-radiopharmaceutical-platform 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nordic-capital-invests-in-minerva-imaging-to-build-global-radiopharmaceutical-platform 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/efgartigimod-shows-promise-in-treating-rare-neurological-autoimmune-disorders-beyond-myasthenia-gravis 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efgartigimod-shows-promise-in-treating-rare-neurological-autoimmune-disorders-beyond-myasthenia-gravis 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hanmi-pharmaceutical-to-present-phase-1-results-of-next-generation-obesity-drugs-at-ada-2025 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-to-present-phase-1-results-of-next-generation-obesity-drugs-at-ada-2025 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/walmart-launches-healthcare-research-institute-to-expand-clinical-trial-access-and-diversity 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/walmart-launches-healthcare-research-institute-to-expand-clinical-trial-access-and-diversity 2025-06-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/resonant-clinical-solutions-names-christophe-berthoux-as-ceo-to-drive-global-expansion 2025-06-09T22:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resonant-clinical-solutions-names-christophe-berthoux-as-ceo-to-drive-global-expansion 2025-06-09T22:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/glycovax-pharma-launches-commercial-production-of-affordable-crm197-protein-for-conjugate-vaccines 2025-06-09T22:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glycovax-pharma-launches-commercial-production-of-affordable-crm197-protein-for-conjugate-vaccines 2025-06-09T22:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-reports-statistically-significant-results-in-breast-cancer-subgroup-from-phase-3-ontarget-trial 2025-06-09T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jaguar-health-reports-statistically-significant-results-in-breast-cancer-subgroup-from-phase-3-ontarget-trial 2025-06-09T21:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-agrees-vivavision-s-phase-2-trial-can-serve-as-pivotal-study-for-vvn461ld-eye-drop 2025-06-09T21:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-agrees-vivavision-s-phase-2-trial-can-serve-as-pivotal-study-for-vvn461ld-eye-drop 2025-06-09T21:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/eluminex-biosciences-reports-positive-phase-1b-results-for-novel-pentavalent-antibody-eb-105-in-diabetic-macular-edema 2025-06-09T21:05:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eluminex-biosciences-reports-positive-phase-1b-results-for-novel-pentavalent-antibody-eb-105-in-diabetic-macular-edema 2025-06-09T21:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/tang-capital-s-concentra-biosciences-acquires-elevation-oncology-for-0-36-per-share-in-latest-biotech-liquidation 2025-06-09T21:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tang-capital-s-concentra-biosciences-acquires-elevation-oncology-for-0-36-per-share-in-latest-biotech-liquidation 2025-06-09T21:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/collplant-expands-stemcell-technologies-partnership-to-include-clinical-and-commercial-applications-of-plant-derived-collagen 2025-06-09T21:05:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/collplant-expands-stemcell-technologies-partnership-to-include-clinical-and-commercial-applications-of-plant-derived-collagen 2025-06-09T21:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-prepares-to-present-pediatric-inhaled-insulin-data-at-ada-scientific-sessions 2025-06-09T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mannkind-prepares-to-present-pediatric-inhaled-insulin-data-at-ada-scientific-sessions 2025-06-09T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-merck-s-enflonsia-for-rsv-prevention-in-infants-with-single-weight-independent-dose 2025-06-09T20:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-merck-s-enflonsia-for-rsv-prevention-in-infants-with-single-weight-independent-dose 2025-06-09T20:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-validates-clinical-trial-outcomes-in-advanced-urothelial-carcinoma-treatment 2025-06-09T20:01:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-validates-clinical-trial-outcomes-in-advanced-urothelial-carcinoma-treatment 2025-06-09T20:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/psilera-partners-with-hesperos-to-advance-organ-on-a-chip-testing-for-frontotemporal-dementia-drug 2025-06-09T19:02:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilera-partners-with-hesperos-to-advance-organ-on-a-chip-testing-for-frontotemporal-dementia-drug 2025-06-09T19:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/concentra-biosciences-to-acquire-elevation-oncology-for-0-36-per-share-plus-contingent-value-rights 2025-06-09T17:20:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concentra-biosciences-to-acquire-elevation-oncology-for-0-36-per-share-plus-contingent-value-rights 2025-06-09T17:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/scottish-health-authority-rejects-alzheimer-s-drug-donanemab-despite-uk-regulatory-approval 2025-06-09T17:16:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scottish-health-authority-rejects-alzheimer-s-drug-donanemab-despite-uk-regulatory-approval 2025-06-09T17:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-s-hemopurifier-shows-promise-for-long-covid-treatment-through-extracellular-vesicle-removal 2025-06-09T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aethlon-medical-s-hemopurifier-shows-promise-for-long-covid-treatment-through-extracellular-vesicle-removal 2025-06-09T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/electric-fields-combined-with-immunotherapy-show-70-survival-improvement-in-glioblastoma-patients 2025-06-09T17:14:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/electric-fields-combined-with-immunotherapy-show-70-survival-improvement-in-glioblastoma-patients 2025-06-09T17:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/mosanna-therapeutics-secures-80m-series-a-to-advance-nasal-spray-treatment-for-obstructive-sleep-apnea 2025-06-09T17:12:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mosanna-therapeutics-secures-80m-series-a-to-advance-nasal-spray-treatment-for-obstructive-sleep-apnea 2025-06-09T17:12:32+00:00 hourly 0.9 https://trial.medpath.com/news/rxmp-therapeutics-advances-hemostatic-agent-rmp-402-with-dod-partnership-and-fda-manufacturing-approval 2025-06-09T17:12:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rxmp-therapeutics-advances-hemostatic-agent-rmp-402-with-dod-partnership-and-fda-manufacturing-approval 2025-06-09T17:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/axio-biopharma-and-likarda-form-strategic-partnership-to-integrate-ai-manufacturing-with-advanced-drug-delivery 2025-06-09T17:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axio-biopharma-and-likarda-form-strategic-partnership-to-integrate-ai-manufacturing-with-advanced-drug-delivery 2025-06-09T17:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/gl-chemtec-completes-state-of-the-art-gmp-facility-to-accelerate-clinical-trial-material-production 2025-06-09T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gl-chemtec-completes-state-of-the-art-gmp-facility-to-accelerate-clinical-trial-material-production 2025-06-09T17:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biopharmaceutical-s-tqc3721-inhalation-drug-receives-phase-iii-approval-for-copd-treatment 2025-06-09T17:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biopharmaceutical-s-tqc3721-inhalation-drug-receives-phase-iii-approval-for-copd-treatment 2025-06-09T17:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/neowise-biotechnology-partners-with-beone-medicines-to-advance-ipsc-based-off-the-shelf-cell-therapies 2025-06-09T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neowise-biotechnology-partners-with-beone-medicines-to-advance-ipsc-based-off-the-shelf-cell-therapies 2025-06-09T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/fable-therapeutics-appoints-former-astrazeneca-executive-david-j-baker-as-chief-scientific-officer 2025-06-09T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fable-therapeutics-appoints-former-astrazeneca-executive-david-j-baker-as-chief-scientific-officer 2025-06-09T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/innospera-pharma-appoints-dr-glenn-crater-as-chief-medical-officer-to-advance-ipf-drug-ing-006 2025-06-09T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innospera-pharma-appoints-dr-glenn-crater-as-chief-medical-officer-to-advance-ipf-drug-ing-006 2025-06-09T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/complement-1-raises-16m-to-scale-ai-powered-cancer-lifestyle-platform-with-90-patient-adherence 2025-06-09T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/complement-1-raises-16m-to-scale-ai-powered-cancer-lifestyle-platform-with-90-patient-adherence 2025-06-09T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/olanzapine-shows-promise-in-preventing-radiation-induced-nausea-and-vomiting-in-phase-3-trial 2025-06-09T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olanzapine-shows-promise-in-preventing-radiation-induced-nausea-and-vomiting-in-phase-3-trial 2025-06-09T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-therapeutics-appoints-gene-therapy-veteran-dr-daniel-chung-as-chief-medical-officer 2025-06-09T17:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beacon-therapeutics-appoints-gene-therapy-veteran-dr-daniel-chung-as-chief-medical-officer 2025-06-09T17:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/citius-oncology-partners-with-cardinal-health-for-lymphir-distribution-ahead-of-commercial-launch 2025-06-09T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citius-oncology-partners-with-cardinal-health-for-lymphir-distribution-ahead-of-commercial-launch 2025-06-09T17:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/tybr-health-secures-fda-510-k-clearance-for-b3-gel-system-to-protect-healing-tissues-in-musculoskeletal-surgery 2025-06-09T17:03:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tybr-health-secures-fda-510-k-clearance-for-b3-gel-system-to-protect-healing-tissues-in-musculoskeletal-surgery 2025-06-09T17:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/avanzanite-partners-with-agios-to-commercialize-first-in-class-pyruvate-kinase-activator-across-europe 2025-06-09T17:02:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avanzanite-partners-with-agios-to-commercialize-first-in-class-pyruvate-kinase-activator-across-europe 2025-06-09T17:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-hla-g-targeted-exosome-therapy-sob100-receives-fda-approval-for-phase-i-cancer-trials 2025-06-09T16:02:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-hla-g-targeted-exosome-therapy-sob100-receives-fda-approval-for-phase-i-cancer-trials 2025-06-09T16:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/circuit-clinical-and-lightship-merge-to-transform-clinical-trial-access-and-delivery 2025-06-09T16:02:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circuit-clinical-and-lightship-merge-to-transform-clinical-trial-access-and-delivery 2025-06-09T16:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-analysis-reveals-brca1-mutation-drives-distinct-tumor-microenvironments-in-triple-negative-breast-cancer 2025-06-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-cell-analysis-reveals-brca1-mutation-drives-distinct-tumor-microenvironments-in-triple-negative-breast-cancer 2025-06-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-factors-drive-early-b-cell-repletion-after-anti-cd20-therapy-in-african-american-ms-patients 2025-06-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-factors-drive-early-b-cell-repletion-after-anti-cd20-therapy-in-african-american-ms-patients 2025-06-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-breaks-ground-on-china-s-first-dual-chamber-lyophilization-manufacturing-site-in-chengdu 2025-06-09T15:01:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-breaks-ground-on-china-s-first-dual-chamber-lyophilization-manufacturing-site-in-chengdu 2025-06-09T15:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/nivolumab-plus-chemotherapy-demonstrates-five-year-survival-benefit-in-resectable-nsclc 2025-06-09T14:59:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nivolumab-plus-chemotherapy-demonstrates-five-year-survival-benefit-in-resectable-nsclc 2025-06-09T14:59:41+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapeutic-classes-transform-future-treatment-paradigm-for-metastatic-castration-resistant-prostate-cancer 2025-06-09T13:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-therapeutic-classes-transform-future-treatment-paradigm-for-metastatic-castration-resistant-prostate-cancer 2025-06-09T13:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/lipocine-s-partner-files-new-drug-submission-for-tlando-in-canada-targeting-700000-annual-trt-prescriptions 2025-06-09T13:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipocine-s-partner-files-new-drug-submission-for-tlando-in-canada-targeting-700000-annual-trt-prescriptions 2025-06-09T13:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-arizona-researchers-identify-drug-candidate-that-reverses-heart-failure-progression-in-mouse-models 2025-06-09T13:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-arizona-researchers-identify-drug-candidate-that-reverses-heart-failure-progression-in-mouse-models 2025-06-09T13:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/nutriband-secures-new-u-s-patent-for-aversa-abuse-deterrent-transdermal-technology 2025-06-09T13:03:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutriband-secures-new-u-s-patent-for-aversa-abuse-deterrent-transdermal-technology 2025-06-09T13:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/metsera-s-met-233i-achieves-8-4-weight-loss-in-phase-1-trial-enabling-first-monthly-amylin-glp-1-combination 2025-06-09T13:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metsera-s-met-233i-achieves-8-4-weight-loss-in-phase-1-trial-enabling-first-monthly-amylin-glp-1-combination 2025-06-09T13:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/secura-bio-initiates-phase-3-terzo-trial-of-copiktra-for-rare-t-cell-lymphoma 2025-06-09T13:02:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/secura-bio-initiates-phase-3-terzo-trial-of-copiktra-for-rare-t-cell-lymphoma 2025-06-09T13:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/seed-therapeutics-appoints-dr-bill-desmarais-as-cfo-and-cbo-to-advance-targeted-protein-degradation-pipeline 2025-06-09T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seed-therapeutics-appoints-dr-bill-desmarais-as-cfo-and-cbo-to-advance-targeted-protein-degradation-pipeline 2025-06-09T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/anlotinib-plus-immune-checkpoint-inhibitors-shows-promise-in-previously-treated-extensive-stage-small-cell-lung-cancer 2025-06-09T13:01:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anlotinib-plus-immune-checkpoint-inhibitors-shows-promise-in-previously-treated-extensive-stage-small-cell-lung-cancer 2025-06-09T13:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-and-recibiopharm-expand-malaria-vaccine-partnership-to-advance-two-blood-stage-candidates 2025-06-09T13:00:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-and-recibiopharm-expand-malaria-vaccine-partnership-to-advance-two-blood-stage-candidates 2025-06-09T13:00:46+00:00 hourly 0.9 https://trial.medpath.com/news/ionq-achieves-20-fold-speedup-in-drug-discovery-simulations-through-quantum-classical-hybrid-computing 2025-06-09T13:00:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionq-achieves-20-fold-speedup-in-drug-discovery-simulations-through-quantum-classical-hybrid-computing 2025-06-09T13:00:44+00:00 hourly 0.9 https://trial.medpath.com/news/ema-reviews-chickenpox-vaccines-after-fatal-encephalitis-case-in-polish-child 2025-06-09T12:59:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-reviews-chickenpox-vaccines-after-fatal-encephalitis-case-in-polish-child 2025-06-09T12:59:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-axsome-s-fibromyalgia-drug-application-due-to-trial-design-issues 2025-06-09T12:58:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-axsome-s-fibromyalgia-drug-application-due-to-trial-design-issues 2025-06-09T12:58:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-triple-combination-hypertension-drug-widaplik-for-initial-treatment 2025-06-09T12:58:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-triple-combination-hypertension-drug-widaplik-for-initial-treatment 2025-06-09T12:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/statins-show-39-mortality-reduction-in-sepsis-patients-large-study-reveals 2025-06-09T12:58:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/statins-show-39-mortality-reduction-in-sepsis-patients-large-study-reveals 2025-06-09T12:58:27+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-enlicitide-shows-promise-as-first-oral-pcsk9-inhibitor-in-phase-3-trials 2025-06-09T12:58:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-enlicitide-shows-promise-as-first-oral-pcsk9-inhibitor-in-phase-3-trials 2025-06-09T12:58:23+00:00 hourly 0.9 https://trial.medpath.com/news/metsera-s-monthly-amylin-injection-achieves-8-4-weight-loss-in-phase-i-trial 2025-06-09T12:58:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metsera-s-monthly-amylin-injection-achieves-8-4-weight-loss-in-phase-i-trial 2025-06-09T12:58:17+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-pharmaceuticals-receives-dcgi-approval-to-launch-brukinsa-for-five-b-cell-malignancies-in-india 2025-06-09T08:58:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-pharmaceuticals-receives-dcgi-approval-to-launch-brukinsa-for-five-b-cell-malignancies-in-india 2025-06-09T08:58:28+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-reports-promising-phase-1b-2a-results-for-ever001-btk-inhibitor-in-primary-membranous-nephropathy 2025-06-09T08:57:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-reports-promising-phase-1b-2a-results-for-ever001-btk-inhibitor-in-primary-membranous-nephropathy 2025-06-09T08:57:54+00:00 hourly 0.9 https://trial.medpath.com/news/ema-extends-shelf-life-of-veterinary-cancer-drug-masivet-to-48-months 2025-06-09T08:57:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-extends-shelf-life-of-veterinary-cancer-drug-masivet-to-48-months 2025-06-09T08:57:50+00:00 hourly 0.9 https://trial.medpath.com/news/advent-international-invests-175-million-in-animal-health-generics-company-felix-pharmaceuticals 2025-06-09T08:57:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advent-international-invests-175-million-in-animal-health-generics-company-felix-pharmaceuticals 2025-06-09T08:57:46+00:00 hourly 0.9 https://trial.medpath.com/news/philippines-fda-expands-vat-free-medicine-list-to-include-new-cancer-diabetes-and-cardiovascular-treatments 2025-06-09T05:05:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philippines-fda-expands-vat-free-medicine-list-to-include-new-cancer-diabetes-and-cardiovascular-treatments 2025-06-09T05:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-pharmaceutical-challenges-vera-therapeutics-in-kidney-disease-race-as-glp-1-drugs-face-eye-safety-scrutiny 2025-06-09T05:05:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-pharmaceutical-challenges-vera-therapeutics-in-kidney-disease-race-as-glp-1-drugs-face-eye-safety-scrutiny 2025-06-09T05:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-partners-with-nipro-to-commercialize-biosimilars-in-japan-including-ustekinumab-candidate 2025-06-09T02:56:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-partners-with-nipro-to-commercialize-biosimilars-in-japan-including-ustekinumab-candidate 2025-06-09T02:56:46+00:00 hourly 0.9 https://trial.medpath.com/news/chronic-gvhd-treatment-evolution-biomarker-guided-therapy-and-steroid-free-approaches-show-promise 2025-06-09T02:55:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chronic-gvhd-treatment-evolution-biomarker-guided-therapy-and-steroid-free-approaches-show-promise 2025-06-09T02:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/revolutionary-gene-therapy-and-bbb-penetrating-treatments-transform-hunter-syndrome-treatment-landscape 2025-06-08T22:00:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolutionary-gene-therapy-and-bbb-penetrating-treatments-transform-hunter-syndrome-treatment-landscape 2025-06-08T22:00:45+00:00 hourly 0.9 https://trial.medpath.com/news/four-promising-gene-and-cell-therapies-challenge-aldurazyme-s-dominance-in-mps-i-treatment 2025-06-08T20:59:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-promising-gene-and-cell-therapies-challenge-aldurazyme-s-dominance-in-mps-i-treatment 2025-06-08T20:59:58+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-pharmaceutical-eyes-combination-therapy-to-set-new-standard-for-obesity-treatment 2025-06-08T13:46:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-pharmaceutical-eyes-combination-therapy-to-set-new-standard-for-obesity-treatment 2025-06-08T13:46:28+00:00 hourly 0.9 https://trial.medpath.com/news/carboplatin-addition-to-standard-chemotherapy-shows-no-survival-benefit-in-triple-negative-breast-cancer 2025-06-08T08:45:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carboplatin-addition-to-standard-chemotherapy-shows-no-survival-benefit-in-triple-negative-breast-cancer 2025-06-08T08:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/uk-doctors-trial-freeze-dried-fecal-microbiota-pills-to-combat-antibiotic-resistant-superbugs 2025-06-08T04:47:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-doctors-trial-freeze-dried-fecal-microbiota-pills-to-combat-antibiotic-resistant-superbugs 2025-06-08T04:47:02+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-two-drug-candidates-for-ultra-rare-x-linked-myopathy-using-zebrafish-model 2025-06-08T04:46:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-two-drug-candidates-for-ultra-rare-x-linked-myopathy-using-zebrafish-model 2025-06-08T04:46:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-elamipretide-for-rare-mitochondrial-disease-despite-patient-improvements 2025-06-08T00:59:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-elamipretide-for-rare-mitochondrial-disease-despite-patient-improvements 2025-06-08T00:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-universities-launch-clinical-trials-testing-psychedelics-for-treatment-resistant-mental-health-disorders 2025-06-07T22:58:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-universities-launch-clinical-trials-testing-psychedelics-for-treatment-resistant-mental-health-disorders 2025-06-07T22:58:32+00:00 hourly 0.9 https://trial.medpath.com/news/uc-berkeley-awards-200000-venture-grant-to-hypo2regen-therapeutics-with-future-investment-option 2025-06-07T21:01:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-berkeley-awards-200000-venture-grant-to-hypo2regen-therapeutics-with-future-investment-option 2025-06-07T21:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/serve-you-rx-adds-two-ustekinumab-biosimilars-to-formulary-offering-up-to-96-cost-savings 2025-06-07T18:59:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serve-you-rx-adds-two-ustekinumab-biosimilars-to-formulary-offering-up-to-96-cost-savings 2025-06-07T18:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/empagliflozin-demonstrates-kidney-safety-across-multiple-patient-populations-new-pooled-analysis-shows 2025-06-07T17:53:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/empagliflozin-demonstrates-kidney-safety-across-multiple-patient-populations-new-pooled-analysis-shows 2025-06-07T17:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/il-12-modified-mrna-vaccines-demonstrate-enhanced-t-cell-activation-in-university-of-pennsylvania-study 2025-06-07T16:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il-12-modified-mrna-vaccines-demonstrate-enhanced-t-cell-activation-in-university-of-pennsylvania-study 2025-06-07T16:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-moderna-s-next-generation-covid-19-vaccine-mrna-1283-with-enhanced-efficacy 2025-06-07T16:45:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-moderna-s-next-generation-covid-19-vaccine-mrna-1283-with-enhanced-efficacy 2025-06-07T16:45:53+00:00 hourly 0.9 https://trial.medpath.com/news/zhengye-biotechnology-completes-6-million-ipo-as-chinese-veterinary-vaccine-manufacturer-enters-us-markets 2025-06-07T15:01:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zhengye-biotechnology-completes-6-million-ipo-as-chinese-veterinary-vaccine-manufacturer-enters-us-markets 2025-06-07T15:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/achieve-trial-shows-spironolactone-fails-to-reduce-cardiovascular-risk-in-dialysis-patients 2025-06-07T13:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/achieve-trial-shows-spironolactone-fails-to-reduce-cardiovascular-risk-in-dialysis-patients 2025-06-07T13:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-5000-crore-prip-scheme-signals-major-shift-from-generic-manufacturing-to-innovation-led-pharma-growth 2025-06-07T12:46:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-5000-crore-prip-scheme-signals-major-shift-from-generic-manufacturing-to-innovation-led-pharma-growth 2025-06-07T12:46:45+00:00 hourly 0.9 https://trial.medpath.com/news/new-screening-algorithms-and-diagnostic-approaches-aim-to-reduce-pulmonary-arterial-hypertension-detection-delays 2025-06-07T12:00:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-screening-algorithms-and-diagnostic-approaches-aim-to-reduce-pulmonary-arterial-hypertension-detection-delays 2025-06-07T12:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-first-of-its-kind-antibody-drug-conjugate-for-multiple-myeloma-treatment 2025-06-07T09:00:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-first-of-its-kind-antibody-drug-conjugate-for-multiple-myeloma-treatment 2025-06-07T09:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-raises-safety-concerns-about-fecal-microbiota-transplants 2025-06-07T08:59:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-raises-safety-concerns-about-fecal-microbiota-transplants 2025-06-07T08:59:26+00:00 hourly 0.9 https://trial.medpath.com/news/uconn-researchers-develop-novel-nanoparticle-mrna-vaccine-platform-for-infectious-bronchitis-virus-in-poultry 2025-06-07T04:59:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uconn-researchers-develop-novel-nanoparticle-mrna-vaccine-platform-for-infectious-bronchitis-virus-in-poultry 2025-06-07T04:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacist-led-interventions-generate-9-million-in-cancer-care-cost-savings-through-remote-clinical-reviews 2025-06-07T03:00:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacist-led-interventions-generate-9-million-in-cancer-care-cost-savings-through-remote-clinical-reviews 2025-06-07T03:00:15+00:00 hourly 0.9 https://trial.medpath.com/news/acip-members-face-termination-as-rfk-jr-s-vaccine-policy-changes-spark-institutional-upheaval 2025-06-07T02:59:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acip-members-face-termination-as-rfk-jr-s-vaccine-policy-changes-spark-institutional-upheaval 2025-06-07T02:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/high-placebo-response-rates-challenge-lupus-drug-development-as-researchers-develop-new-trial-strategies 2025-06-07T02:59:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-placebo-response-rates-challenge-lupus-drug-development-as-researchers-develop-new-trial-strategies 2025-06-07T02:59:34+00:00 hourly 0.9 https://trial.medpath.com/news/mission-bio-secures-funding-to-advance-single-cell-tri-omics-platform-for-cancer-drug-development 2025-06-07T02:59:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mission-bio-secures-funding-to-advance-single-cell-tri-omics-platform-for-cancer-drug-development 2025-06-07T02:59:26+00:00 hourly 0.9 https://trial.medpath.com/news/first-ascent-biomedical-partners-with-fight-colorectal-cancer-for-350000-precision-medicine-study 2025-06-07T01:59:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-ascent-biomedical-partners-with-fight-colorectal-cancer-for-350000-precision-medicine-study 2025-06-07T01:59:20+00:00 hourly 0.9 https://trial.medpath.com/news/church-dwight-recalls-zicam-and-orajel-nasal-swabs-due-to-fungal-contamination-risk 2025-06-07T01:04:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/church-dwight-recalls-zicam-and-orajel-nasal-swabs-due-to-fungal-contamination-risk 2025-06-07T01:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-immunotherapy-plus-chemotherapy-improves-long-term-survival-in-operable-nsclc 2025-06-07T01:03:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-immunotherapy-plus-chemotherapy-improves-long-term-survival-in-operable-nsclc 2025-06-07T01:03:15+00:00 hourly 0.9 https://trial.medpath.com/news/powers-health-partners-with-profound-research-to-establish-clinical-research-center-in-northwest-indiana 2025-06-07T00:57:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/powers-health-partners-with-profound-research-to-establish-clinical-research-center-in-northwest-indiana 2025-06-07T00:57:54+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-raises-mid-term-sales-outlook-to-6-growth-through-2029-on-pipeline-strength 2025-06-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-raises-mid-term-sales-outlook-to-6-growth-through-2029-on-pipeline-strength 2025-06-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nkarta-appoints-immunology-expert-shawn-rose-as-chief-medical-officer-to-lead-autoimmune-nk-cell-therapy-development 2025-06-06T20:50:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nkarta-appoints-immunology-expert-shawn-rose-as-chief-medical-officer-to-lead-autoimmune-nk-cell-therapy-development 2025-06-06T20:50:23+00:00 hourly 0.9 https://trial.medpath.com/news/brenntag-specialties-acquires-czech-firm-mcepharma-to-expand-gmp-capabilities-across-emea-region 2025-06-06T20:50:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brenntag-specialties-acquires-czech-firm-mcepharma-to-expand-gmp-capabilities-across-emea-region 2025-06-06T20:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-cancels-766-million-mrna-bird-flu-vaccine-contract-with-moderna 2025-06-06T20:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-cancels-766-million-mrna-bird-flu-vaccine-contract-with-moderna 2025-06-06T20:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-transfers-66-million-patent-dispute-between-alkermes-and-acorda-therapeutics 2025-06-06T20:48:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-transfers-66-million-patent-dispute-between-alkermes-and-acorda-therapeutics 2025-06-06T20:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/bionet-and-bio-farma-partner-to-accelerate-tdap-vaccine-access-across-southeast-asia 2025-06-06T20:48:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionet-and-bio-farma-partner-to-accelerate-tdap-vaccine-access-across-southeast-asia 2025-06-06T20:48:30+00:00 hourly 0.9 https://trial.medpath.com/news/major-pbms-exclude-humira-biosimilars-from-2025-formularies-favor-private-label-products 2025-06-06T20:47:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pbms-exclude-humira-biosimilars-from-2025-formularies-favor-private-label-products 2025-06-06T20:47:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-kura-oncology-s-nda-for-ziftomenib-in-npm1-mutant-aml-with-priority-review 2025-06-06T20:47:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-kura-oncology-s-nda-for-ziftomenib-in-npm1-mutant-aml-with-priority-review 2025-06-06T20:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/ai-integration-and-advanced-drug-delivery-systems-reshape-pharmaceutical-outsourcing-models 2025-06-06T20:47:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-integration-and-advanced-drug-delivery-systems-reshape-pharmaceutical-outsourcing-models 2025-06-06T20:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/transcatheter-pda-closure-shows-comparable-respiratory-outcomes-to-surgery-in-preterm-infants 2025-06-06T20:46:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcatheter-pda-closure-shows-comparable-respiratory-outcomes-to-surgery-in-preterm-infants 2025-06-06T20:46:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-phathom-pharmaceuticals-10-year-market-exclusivity-for-voquezna-through-2032 2025-06-06T20:46:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-phathom-pharmaceuticals-10-year-market-exclusivity-for-voquezna-through-2032 2025-06-06T20:46:34+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-raises-250-million-in-largest-hong-kong-biopharma-follow-on-offering-in-12-months 2025-06-06T19:59:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelun-biotech-raises-250-million-in-largest-hong-kong-biopharma-follow-on-offering-in-12-months 2025-06-06T19:59:25+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-s-sibeprenlimab-achieves-51-reduction-in-proteinuria-for-iga-nephropathy-intensifying-competition-with-vera-therapeutics 2025-06-06T18:58:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-s-sibeprenlimab-achieves-51-reduction-in-proteinuria-for-iga-nephropathy-intensifying-competition-with-vera-therapeutics 2025-06-06T18:58:15+00:00 hourly 0.9 https://trial.medpath.com/news/fidaxomicin-demonstrates-superior-efficacy-in-reducing-c-difficile-recurrence-among-high-risk-patients 2025-06-06T17:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fidaxomicin-demonstrates-superior-efficacy-in-reducing-c-difficile-recurrence-among-high-risk-patients 2025-06-06T17:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-to-present-phase-3-hemophilia-trial-data-at-isth-2025-congress 2025-06-06T17:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-to-present-phase-3-hemophilia-trial-data-at-isth-2025-congress 2025-06-06T17:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/mckesson-corporation-completes-acquisition-of-florida-cancer-specialists-to-strengthen-community-oncology-network 2025-06-06T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mckesson-corporation-completes-acquisition-of-florida-cancer-specialists-to-strengthen-community-oncology-network 2025-06-06T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-strengthens-board-with-industry-veteran-ahead-of-key-bla-submission 2025-06-06T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-strengthens-board-with-industry-veteran-ahead-of-key-bla-submission 2025-06-06T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/pci-pharma-services-unveils-advanced-sterile-manufacturing-facility-to-boost-biologic-production-capacity 2025-06-06T17:02:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pci-pharma-services-unveils-advanced-sterile-manufacturing-facility-to-boost-biologic-production-capacity 2025-06-06T17:02:16+00:00 hourly 0.9 https://trial.medpath.com/news/mit-and-recursion-release-boltz-2-open-source-ai-model-achieves-1000x-speed-boost-in-drug-discovery-screening 2025-06-06T17:01:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mit-and-recursion-release-boltz-2-open-source-ai-model-achieves-1000x-speed-boost-in-drug-discovery-screening 2025-06-06T17:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/vivoryon-s-varoglutamstat-shows-sustained-kidney-function-improvement-in-phase-2-meta-analysis 2025-06-06T17:00:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivoryon-s-varoglutamstat-shows-sustained-kidney-function-improvement-in-phase-2-meta-analysis 2025-06-06T17:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/aytu-biopharma-secures-exclusive-rights-to-first-in-class-antidepressant-exxua-for-22b-us-market 2025-06-06T17:00:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aytu-biopharma-secures-exclusive-rights-to-first-in-class-antidepressant-exxua-for-22b-us-market 2025-06-06T17:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/aytu-biopharma-raises-16-6m-to-launch-first-in-class-depression-treatment-exxua 2025-06-06T16:59:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aytu-biopharma-raises-16-6m-to-launch-first-in-class-depression-treatment-exxua 2025-06-06T16:59:27+00:00 hourly 0.9 https://trial.medpath.com/news/nemluvio-shows-sustained-long-term-efficacy-in-atopic-dermatitis-with-two-year-extension-data 2025-06-06T13:01:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nemluvio-shows-sustained-long-term-efficacy-in-atopic-dermatitis-with-two-year-extension-data 2025-06-06T13:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/denovo-biopharma-forms-neuroscience-advisory-board-to-advance-precision-medicine-approach-for-treatment-resistant-depression 2025-06-06T13:00:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denovo-biopharma-forms-neuroscience-advisory-board-to-advance-precision-medicine-approach-for-treatment-resistant-depression 2025-06-06T13:00:37+00:00 hourly 0.9 https://trial.medpath.com/news/glycomimetics-stockholders-approve-merger-with-crescent-biopharma-creating-new-oncology-focused-entity 2025-06-06T13:00:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glycomimetics-stockholders-approve-merger-with-crescent-biopharma-creating-new-oncology-focused-entity 2025-06-06T13:00:28+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-biopharma-sector-showcases-innovation-leadership-at-bioseedin-2025-conference 2025-06-06T12:59:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-biopharma-sector-showcases-innovation-leadership-at-bioseedin-2025-conference 2025-06-06T12:59:47+00:00 hourly 0.9 https://trial.medpath.com/news/htl-biotechnology-launches-eur12-million-sterile-hyaluronic-acid-production-line-to-enable-heat-sensitive-drug-combinations 2025-06-06T12:59:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/htl-biotechnology-launches-eur12-million-sterile-hyaluronic-acid-production-line-to-enable-heat-sensitive-drug-combinations 2025-06-06T12:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/geneditbio-doses-first-patient-in-world-s-first-in-vivo-crispr-trial-for-tgfbi-corneal-dystrophy 2025-06-06T12:59:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geneditbio-doses-first-patient-in-world-s-first-in-vivo-crispr-trial-for-tgfbi-corneal-dystrophy 2025-06-06T12:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/immune-thrombocytopenia-presents-diagnostic-challenges-with-unpredictable-disease-course 2025-06-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-thrombocytopenia-presents-diagnostic-challenges-with-unpredictable-disease-course 2025-06-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bitbiome-partners-with-leading-cmo-to-enable-large-scale-biomanufacturing-of-microbial-derived-products 2025-06-06T11:59:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bitbiome-partners-with-leading-cmo-to-enable-large-scale-biomanufacturing-of-microbial-derived-products 2025-06-06T11:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/pyx-health-acquires-farmboxrx-in-47-5m-deal-to-combat-health-disparities-through-food-based-care 2025-06-06T09:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pyx-health-acquires-farmboxrx-in-47-5m-deal-to-combat-health-disparities-through-food-based-care 2025-06-06T09:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/hemispherian-s-glix1-receives-ema-orphan-drug-designation-for-glioma-treatment 2025-06-06T09:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemispherian-s-glix1-receives-ema-orphan-drug-designation-for-glioma-treatment 2025-06-06T09:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/penumbra-launches-ruby-xl-system-the-largest-embolization-coil-platform-for-vascular-procedures 2025-06-06T09:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penumbra-launches-ruby-xl-system-the-largest-embolization-coil-platform-for-vascular-procedures 2025-06-06T09:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/elgan-pharma-and-chiesi-begin-phase-3-trial-of-elgn-2112-for-intestinal-malabsorption-in-preterm-infants 2025-06-06T09:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elgan-pharma-and-chiesi-begin-phase-3-trial-of-elgn-2112-for-intestinal-malabsorption-in-preterm-infants 2025-06-06T09:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/improved-pharma-completes-fifth-expansion-at-kurz-purdue-technology-center-now-occupying-over-5500-square-feet 2025-06-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/improved-pharma-completes-fifth-expansion-at-kurz-purdue-technology-center-now-occupying-over-5500-square-feet 2025-06-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-receives-regulatory-approval-for-triple-combination-cancer-therapy-trial 2025-06-06T07:00:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abl-bio-receives-regulatory-approval-for-triple-combination-cancer-therapy-trial 2025-06-06T07:00:06+00:00 hourly 0.9 https://trial.medpath.com/news/abilitypharma-s-ibrilatazar-doubles-overall-survival-in-squamous-non-small-cell-lung-cancer-trial 2025-06-06T05:58:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abilitypharma-s-ibrilatazar-doubles-overall-survival-in-squamous-non-small-cell-lung-cancer-trial 2025-06-06T05:58:12+00:00 hourly 0.9 https://trial.medpath.com/news/foldax-receives-world-s-first-approval-for-polymer-heart-valve-in-india 2025-06-06T04:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foldax-receives-world-s-first-approval-for-polymer-heart-valve-in-india 2025-06-06T04:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-injectable-antipsychotics-proposed-as-new-standard-of-care-for-schizophrenia-treatment 2025-06-06T04:58:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-injectable-antipsychotics-proposed-as-new-standard-of-care-for-schizophrenia-treatment 2025-06-06T04:58:54+00:00 hourly 0.9 https://trial.medpath.com/news/prophase-labs-forms-clinical-advisory-board-to-advance-be-smart-esophageal-cancer-diagnostic-platform 2025-06-06T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prophase-labs-forms-clinical-advisory-board-to-advance-be-smart-esophageal-cancer-diagnostic-platform 2025-06-06T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/seyltx-advances-chronic-cough-pipeline-with-optimized-ifenprodil-dosing-and-strategic-neurop-partnership 2025-06-06T03:05:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seyltx-advances-chronic-cough-pipeline-with-optimized-ifenprodil-dosing-and-strategic-neurop-partnership 2025-06-06T03:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/insurance-prior-authorization-delays-cancer-treatment-by-up-to-two-weeks-forcing-suboptimal-care-decisions 2025-06-06T03:04:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insurance-prior-authorization-delays-cancer-treatment-by-up-to-two-weeks-forcing-suboptimal-care-decisions 2025-06-06T03:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharma-presents-72-studies-at-asco-2025-demonstrating-broad-oncology-pipeline-impact 2025-06-06T03:02:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-pharma-presents-72-studies-at-asco-2025-demonstrating-broad-oncology-pipeline-impact 2025-06-06T03:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/adolescent-obesity-medication-prescriptions-surge-301-despite-persistent-access-barriers 2025-06-06T02:01:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adolescent-obesity-medication-prescriptions-surge-301-despite-persistent-access-barriers 2025-06-06T02:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biotech-s-padeliporfin-vtp-therapy-enables-surgical-resection-in-previously-inoperable-pancreatic-cancer-patient 2025-06-06T00:51:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-biotech-s-padeliporfin-vtp-therapy-enables-surgical-resection-in-previously-inoperable-pancreatic-cancer-patient 2025-06-06T00:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-tecentriq-cuts-colon-cancer-recurrence-by-50-in-patients-with-dna-repair-defects 2025-06-06T00:50:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-tecentriq-cuts-colon-cancer-recurrence-by-50-in-patients-with-dna-repair-defects 2025-06-06T00:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/lenacapavir-shows-100-efficacy-in-hiv-prevention-with-twice-yearly-injection 2025-06-06T00:49:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenacapavir-shows-100-efficacy-in-hiv-prevention-with-twice-yearly-injection 2025-06-06T00:49:59+00:00 hourly 0.9 https://trial.medpath.com/news/zeiss-clarus-700-ultra-widefield-retinal-imaging-system-receives-nmpa-approval-in-china 2025-06-06T00:49:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeiss-clarus-700-ultra-widefield-retinal-imaging-system-receives-nmpa-approval-in-china 2025-06-06T00:49:20+00:00 hourly 0.9 https://trial.medpath.com/news/signify-bio-launches-with-15m-funding-to-develop-in-situ-protein-therapeutics-platform 2025-06-06T00:47:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/signify-bio-launches-with-15m-funding-to-develop-in-situ-protein-therapeutics-platform 2025-06-06T00:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-gras-clearance-for-omniactive-s-lutemax-free-lutein-in-infant-formula 2025-06-06T00:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-gras-clearance-for-omniactive-s-lutemax-free-lutein-in-infant-formula 2025-06-06T00:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/inka-health-launches-global-ai-oncology-consortium-to-advance-predictive-cancer-research 2025-06-06T00:47:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inka-health-launches-global-ai-oncology-consortium-to-advance-predictive-cancer-research 2025-06-06T00:47:16+00:00 hourly 0.9 https://trial.medpath.com/news/bytebrain-launches-medrail-ai-platform-to-transform-clinical-trial-operations 2025-06-06T00:46:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bytebrain-launches-medrail-ai-platform-to-transform-clinical-trial-operations 2025-06-06T00:46:07+00:00 hourly 0.9 https://trial.medpath.com/news/humacyte-s-bioengineered-vessel-shows-superior-performance-in-high-risk-dialysis-patients 2025-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/humacyte-s-bioengineered-vessel-shows-superior-performance-in-high-risk-dialysis-patients 2025-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-faces-major-setback-as-cell-therapy-amtagvi-commercial-launch-struggles 2025-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-biotherapeutics-faces-major-setback-as-cell-therapy-amtagvi-commercial-launch-struggles 2025-06-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-medtronic-s-enhanced-visualase-v2-mri-guided-laser-ablation-system-for-brain-surgery 2025-06-05T23:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-medtronic-s-enhanced-visualase-v2-mri-guided-laser-ablation-system-for-brain-surgery 2025-06-05T23:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/p2y12-inhibitors-show-23-reduction-in-cardiovascular-events-compared-to-aspirin-in-post-stent-patients 2025-06-05T22:03:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/p2y12-inhibitors-show-23-reduction-in-cardiovascular-events-compared-to-aspirin-in-post-stent-patients 2025-06-05T22:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-ai-tool-elsa-for-drug-reviews-while-novo-nordisk-struggles-in-obesity-market-competition 2025-06-05T22:03:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-ai-tool-elsa-for-drug-reviews-while-novo-nordisk-struggles-in-obesity-market-competition 2025-06-05T22:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/first-clinical-trial-shows-nicotinamide-riboside-improves-multiple-health-outcomes-in-werner-syndrome-patients 2025-06-05T22:02:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-clinical-trial-shows-nicotinamide-riboside-improves-multiple-health-outcomes-in-werner-syndrome-patients 2025-06-05T22:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/nrg-oncology-trial-shows-regional-nodal-radiation-provides-no-benefit-for-breast-cancer-patients-with-node-conversion-after-neoadjuvant-chemotherapy 2025-06-05T22:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nrg-oncology-trial-shows-regional-nodal-radiation-provides-no-benefit-for-breast-cancer-patients-with-node-conversion-after-neoadjuvant-chemotherapy 2025-06-05T22:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-study-shows-81-success-rate-for-pfo-closure-in-drug-resistant-migraine-patients 2025-06-05T21:02:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-study-shows-81-success-rate-for-pfo-closure-in-drug-resistant-migraine-patients 2025-06-05T21:02:40+00:00 hourly 0.9 https://trial.medpath.com/news/kennedy-pledges-accelerated-fda-approvals-for-rare-disease-therapies-to-maintain-us-biotech-leadership 2025-06-05T20:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kennedy-pledges-accelerated-fda-approvals-for-rare-disease-therapies-to-maintain-us-biotech-leadership 2025-06-05T20:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/plt-health-solutions-serezin-shows-significant-sleep-and-pain-relief-benefits-in-clinical-trial 2025-06-05T20:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plt-health-solutions-serezin-shows-significant-sleep-and-pain-relief-benefits-in-clinical-trial 2025-06-05T20:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/cns-pharmaceuticals-presents-brain-penetrating-taxane-tpi-287-for-glioblastoma-treatment-at-2025-brain-tumor-summit 2025-06-05T20:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cns-pharmaceuticals-presents-brain-penetrating-taxane-tpi-287-for-glioblastoma-treatment-at-2025-brain-tumor-summit 2025-06-05T20:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-s-fabp5-inhibitor-art26-12-shows-comparable-efficacy-to-naproxen-in-osteoarthritis-pain-study 2025-06-05T19:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artelo-s-fabp5-inhibitor-art26-12-shows-comparable-efficacy-to-naproxen-in-osteoarthritis-pain-study 2025-06-05T19:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/dr-elizabeth-mittendorf-outlines-vision-as-asco-president-elect-to-advance-multidisciplinary-cancer-care-and-workforce-support 2025-06-05T17:57:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-elizabeth-mittendorf-outlines-vision-as-asco-president-elect-to-advance-multidisciplinary-cancer-care-and-workforce-support 2025-06-05T17:57:53+00:00 hourly 0.9 https://trial.medpath.com/news/upstream-bio-presents-data-showing-verekitug-s-superior-potency-through-tslp-receptor-targeting-at-eaaci-congress 2025-06-05T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upstream-bio-presents-data-showing-verekitug-s-superior-potency-through-tslp-receptor-targeting-at-eaaci-congress 2025-06-05T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-s-chikungunya-vaccine-shows-sustained-antibody-response-in-children-after-six-months 2025-06-05T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-s-chikungunya-vaccine-shows-sustained-antibody-response-in-children-after-six-months 2025-06-05T17:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/casma-therapeutics-nominates-first-in-class-trpml1-agonist-csm-101-for-parkinson-s-disease-treatment 2025-06-05T17:10:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/casma-therapeutics-nominates-first-in-class-trpml1-agonist-csm-101-for-parkinson-s-disease-treatment 2025-06-05T17:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/qurebio-secures-14-million-series-c1-funding-to-advance-bispecific-antibody-pipeline 2025-06-05T17:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qurebio-secures-14-million-series-c1-funding-to-advance-bispecific-antibody-pipeline 2025-06-05T17:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/allay-therapeutics-secures-57-5m-series-d-to-advance-ultra-sustained-pain-management-platform 2025-06-05T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allay-therapeutics-secures-57-5m-series-d-to-advance-ultra-sustained-pain-management-platform 2025-06-05T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/linear-diagnostics-secures-ps1m-to-advance-5-minute-sti-diagnostic-test 2025-06-05T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/linear-diagnostics-secures-ps1m-to-advance-5-minute-sti-diagnostic-test 2025-06-05T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/mandatory-human-abuse-liability-assessment-reshapes-drug-development-strategy-and-regulatory-compliance 2025-06-05T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mandatory-human-abuse-liability-assessment-reshapes-drug-development-strategy-and-regulatory-compliance 2025-06-05T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/iperionx-secures-99m-defense-contract-for-domestic-titanium-manufacturing 2025-06-05T17:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iperionx-secures-99m-defense-contract-for-domestic-titanium-manufacturing 2025-06-05T17:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/veongen-therapeutics-receives-fda-rare-pediatric-disease-designation-for-stargardt-disease-gene-therapy-vg801 2025-06-05T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veongen-therapeutics-receives-fda-rare-pediatric-disease-designation-for-stargardt-disease-gene-therapy-vg801 2025-06-05T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/scinai-immunotherapeutics-surges-104-following-italian-regulatory-clearance-for-pincell-acquisition 2025-06-05T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scinai-immunotherapeutics-surges-104-following-italian-regulatory-clearance-for-pincell-acquisition 2025-06-05T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/uk-drug-regulator-issues-first-contraception-warning-for-weight-loss-injections-after-40-pregnancy-reports 2025-06-05T17:03:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-drug-regulator-issues-first-contraception-warning-for-weight-loss-injections-after-40-pregnancy-reports 2025-06-05T17:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/immunoprecise-achieves-ai-driven-breakthrough-in-universal-dengue-vaccine-discovery 2025-06-05T17:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunoprecise-achieves-ai-driven-breakthrough-in-universal-dengue-vaccine-discovery 2025-06-05T17:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/cresemba-antifungal-drug-achieves-record-global-sales-triggers-2-5m-milestone-payment-to-basilea 2025-06-05T15:00:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cresemba-antifungal-drug-achieves-record-global-sales-triggers-2-5m-milestone-payment-to-basilea 2025-06-05T15:00:54+00:00 hourly 0.9 https://trial.medpath.com/news/osivax-completes-phase-2a-booster-trial-for-broad-spectrum-influenza-vaccine-ovx836 2025-06-05T14:59:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osivax-completes-phase-2a-booster-trial-for-broad-spectrum-influenza-vaccine-ovx836 2025-06-05T14:59:10+00:00 hourly 0.9 https://trial.medpath.com/news/cellectar-biosciences-raises-2-5-million-through-warrant-exercise-to-advance-cancer-drug-development 2025-06-05T14:04:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellectar-biosciences-raises-2-5-million-through-warrant-exercise-to-advance-cancer-drug-development 2025-06-05T14:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/cancervax-achieves-breakthrough-in-targeted-nanoparticle-development-for-universal-cancer-treatment 2025-06-05T12:50:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancervax-achieves-breakthrough-in-targeted-nanoparticle-development-for-universal-cancer-treatment 2025-06-05T12:50:22+00:00 hourly 0.9 https://trial.medpath.com/news/biocytogen-secures-japan-patent-for-renmab-platform-strengthening-global-ip-portfolio-for-fully-human-antibody-discovery 2025-06-05T12:49:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocytogen-secures-japan-patent-for-renmab-platform-strengthening-global-ip-portfolio-for-fully-human-antibody-discovery 2025-06-05T12:49:19+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-secures-patent-protection-for-wakix-through-2030-settlement-with-lupin 2025-06-05T12:49:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmony-biosciences-secures-patent-protection-for-wakix-through-2030-settlement-with-lupin 2025-06-05T12:49:17+00:00 hourly 0.9 https://trial.medpath.com/news/mitochondrial-dna-variant-predicts-immunotherapy-resistance-in-metastatic-melanoma 2025-06-05T12:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitochondrial-dna-variant-predicts-immunotherapy-resistance-in-metastatic-melanoma 2025-06-05T12:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/mediar-therapeutics-initiates-phase-2-trial-of-first-in-class-anti-wisp1-antibody-for-idiopathic-pulmonary-fibrosis 2025-06-05T12:48:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediar-therapeutics-initiates-phase-2-trial-of-first-in-class-anti-wisp1-antibody-for-idiopathic-pulmonary-fibrosis 2025-06-05T12:48:32+00:00 hourly 0.9 https://trial.medpath.com/news/kiniksa-pharmaceuticals-advances-kpl-387-phase-2-3-trial-for-recurrent-pericarditis 2025-06-05T12:47:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiniksa-pharmaceuticals-advances-kpl-387-phase-2-3-trial-for-recurrent-pericarditis 2025-06-05T12:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/juvenescence-acquires-ai-drug-discovery-company-ro5-to-accelerate-age-related-disease-pipeline 2025-06-05T12:45:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/juvenescence-acquires-ai-drug-discovery-company-ro5-to-accelerate-age-related-disease-pipeline 2025-06-05T12:45:29+00:00 hourly 0.9 https://trial.medpath.com/news/confidence-study-shows-superior-kidney-protection-with-combined-finerenone-and-sglt-2-inhibitor-therapy 2025-06-05T12:44:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/confidence-study-shows-superior-kidney-protection-with-combined-finerenone-and-sglt-2-inhibitor-therapy 2025-06-05T12:44:48+00:00 hourly 0.9 https://trial.medpath.com/news/kiora-pharmaceuticals-partners-with-senju-for-kio-301-development-in-asian-markets-worth-over-110-million 2025-06-05T12:44:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiora-pharmaceuticals-partners-with-senju-for-kio-301-development-in-asian-markets-worth-over-110-million 2025-06-05T12:44:45+00:00 hourly 0.9 https://trial.medpath.com/news/bnt327-pm8002-bispecific-antibody-shows-promising-activity-in-unresectable-mesothelioma 2025-06-05T12:44:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bnt327-pm8002-bispecific-antibody-shows-promising-activity-in-unresectable-mesothelioma 2025-06-05T12:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-secures-161m-gene-therapy-licensing-deal-for-ocu400-in-korean-market 2025-06-05T12:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocugen-secures-161m-gene-therapy-licensing-deal-for-ocu400-in-korean-market 2025-06-05T12:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/servier-india-launches-first-in-class-idh1-targeted-therapy-ivosidenib-for-rare-blood-and-bile-duct-cancers 2025-06-05T12:06:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-india-launches-first-in-class-idh1-targeted-therapy-ivosidenib-for-rare-blood-and-bile-duct-cancers 2025-06-05T12:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-hundreds-of-drugs-without-adequate-evidence-of-effectiveness-investigation-reveals 2025-06-05T12:06:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-hundreds-of-drugs-without-adequate-evidence-of-effectiveness-investigation-reveals 2025-06-05T12:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-researchers-pioneer-multiomics-based-cancer-treatment-predictions-in-first-of-kind-clinical-study 2025-06-05T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swiss-researchers-pioneer-multiomics-based-cancer-treatment-predictions-in-first-of-kind-clinical-study 2025-06-05T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/fujirebio-partners-with-stanford-medicine-to-advance-ultrasensitive-infectious-disease-diagnostics 2025-06-05T10:59:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujirebio-partners-with-stanford-medicine-to-advance-ultrasensitive-infectious-disease-diagnostics 2025-06-05T10:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/clarity-pharmaceuticals-64cu-sartate-shows-superior-lesion-detection-in-phase-ii-disco-trial-for-neuroendocrine-tumors 2025-06-05T10:00:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clarity-pharmaceuticals-64cu-sartate-shows-superior-lesion-detection-in-phase-ii-disco-trial-for-neuroendocrine-tumors 2025-06-05T10:00:16+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-therapeutics-licenses-bcma-targeted-bispecific-t-cell-engager-for-autoimmune-disease-development 2025-06-05T09:59:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cullinan-therapeutics-licenses-bcma-targeted-bispecific-t-cell-engager-for-autoimmune-disease-development 2025-06-05T09:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytic-virus-cancer-therapy-pipeline-shows-strong-growth-with-120-companies-developing-125-treatments 2025-06-05T09:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncolytic-virus-cancer-therapy-pipeline-shows-strong-growth-with-120-companies-developing-125-treatments 2025-06-05T09:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/kancera-receives-fda-fast-track-eligibility-for-kand567-in-heart-attack-treatment 2025-06-05T08:58:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kancera-receives-fda-fast-track-eligibility-for-kand567-in-heart-attack-treatment 2025-06-05T08:58:50+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-and-alvotech-partner-to-develop-keytruda-biosimilar-in-29-5-billion-market 2025-06-05T08:58:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-and-alvotech-partner-to-develop-keytruda-biosimilar-in-29-5-billion-market 2025-06-05T08:58:16+00:00 hourly 0.9 https://trial.medpath.com/news/mgi-tech-expands-partnership-with-brazil-s-fiocruz-to-enhance-genetic-sequencing-for-cancer-and-infectious-disease-diagnostics 2025-06-05T08:11:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mgi-tech-expands-partnership-with-brazil-s-fiocruz-to-enhance-genetic-sequencing-for-cancer-and-infectious-disease-diagnostics 2025-06-05T08:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/melbourne-researchers-develop-mrna-technology-to-force-hiv-out-of-cellular-hiding-places 2025-06-05T08:11:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/melbourne-researchers-develop-mrna-technology-to-force-hiv-out-of-cellular-hiding-places 2025-06-05T08:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-s-ranivisio-becomes-first-lucentis-biosimilar-approved-in-brazil 2025-06-05T08:11:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-s-ranivisio-becomes-first-lucentis-biosimilar-approved-in-brazil 2025-06-05T08:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/astrivax-therapeutics-launches-phase-i-trial-of-avx70371-hepatitis-b-immunotherapy 2025-06-05T08:11:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrivax-therapeutics-launches-phase-i-trial-of-avx70371-hepatitis-b-immunotherapy 2025-06-05T08:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/livanova-s-core-vns-study-demonstrates-sustained-seizure-reduction-in-drug-resistant-epilepsy-patients 2025-06-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/livanova-s-core-vns-study-demonstrates-sustained-seizure-reduction-in-drug-resistant-epilepsy-patients 2025-06-05T08:00:00+00:00 hourly 0.9